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SYNOPSIS
1The work incorporated in the thesis with the title "STUDIES ON
HETEROCYCLIC ENTITIES OF MEDICINAL INTEREST" has been
described as under :
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON FURANS
[A] STUDIES ON PYRAZOLES
Pyrazole derivatives represent one of modest classes of compounds
possessing wide range of therapeutic activities such as antimicrobial,
antitubercular, hypnotic, anthelmintics and antithyroid. Pyrazole derivaties
are also used as insecticidal and herbicidal etc.
Considering the increasing importance of pyrazole nucleus, we have
undertaken synthesis of some novel hydrazones, azomethines, oxadiazoles,
imidazolinones, sulphonamides, arylamides and nitriles bearing pyrazole
moiety.
PART - I : STUDIES ON AZOMETHINES
The schiff bases have been proven to be of great importance in
exhibiting and enhancing the pharmacological activity such as antibiotic,
antidepressant, sedative, hypnotic, anticonvulsant.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Anisyl-5-substituted benzalhydrazinocarbonyl
pyrazoles







Schiff bases of type (I) have been synthesised by the condensation of
3-p-anisyl-5-hydrazino carbonyl pyrazole with various aromatic aldehydes.
PART - II : STUDIES ON OXADIAZOLYL PYRAZOLES
1,3 ,4-Oxadiazo les  are  assoc ia ted wi th  broad spec t rum of
pharmacological  act iv i ty l ike anaesthet ic,  hypnotic,  ant ibacter ia l ,
hypoglycemic & antifungal. These valid observations prompted as to
synthesise 1,3,4- oxadiazole derivatives with better therapeutic value have
been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
An i sy l -5 - (5 ' - a r y l -1 ' , 3 ' , 4 ' - oxad iazo l -2 ' - y l )
pyrazoles
The oxadiazole derivatives of type (II) have been synthesised by the
condensation of 3-p-anisyl-5-hydrazino carbonyl pyrazole with various
aromatic acids in the presence of POCl3.
PART - III : STUDIES ON IMIDAZOLINYL PYRAZOLES
Imidazolinone derivatives are reported to be active as anticonvulsant,
sedative, hypnotic, potent CNS depresent antihistamine, antiinflammatory
and as mono oxidase (MAO) inhibitors. In order to develop medicinally
important compounds, it was considered of interest to synthesise some








R = ArylType (II)
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
A n i s y l - 5 - ( 2 ' - p h e n y l - 4 ' - a r y l i d e n e - 5 ' - o x o -
imidazolin-1'-yl aminocarbonyl) pyrazoles
The imidazoline derivatives of type (III) have been prepared by the
condensation of 3-p-anisyl-5-hydrazino carbonyl pyrazole with substituted
azalactones.
PART - IV : STUDIES ON PYRAZOLONES
Pyrazolone derivatives are associated with broad spectrum of
pharmacological activities like herbicidal, antithyroid, antitubercular,
antifungal and antibiotic etc. In view of the above findings and to achieve
better potency, different types of pyrazolones have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Anisyl-5-(3'-methyl-4'-arylhydrazono-5'-oxo-
pyrazol-1'yl carbonyl) pyrazoles




















R = ArylType (IV)
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The pyrazolone derivatives of type (IV) have been prepared by
condensation of  3-p-anisyl-5-hydrazino carbonyl pyrazole with different 2-
(arylhydrazono)-ethyl-3-oxobutanoate.
PART - V : STUDIES ON SULPHONAMIDES
Recently interest has been developed in sulphonamide drugs for the
cure of diseases like tuberculosis, diabetes, malaria, leprosy and epilepsy.
These findings promated us to synthesise some representative sulphonamide
derivatives possessing better therapeutic value which have been described
as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Anisyl-5-(arylsulphonylhydrazinocarbonyl)
pyrazoles
Sulphonamides of type (V) have been prepared by the condensation
of 3-p-anisyl-5-hydrazino carbonyl pyrazole with different aromatic










R = ArylType (V)
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PART - VI: STUDIES ON ARYLAMIDES
Arylamides are associated with various pharmacological activities such
as anaesthet ic ,  ant ibacter ia l ,  ant iv i ra l ,  ant ipyret ics ,  ant iamoebic,
anticonvulsant and analgesic. These observations led us to link different
aryl acid chlorides with 3-p-anisyl-5-hydrazino carbonyl pyrazole.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Anisyl-5-(aroylhydrazinocarbonyl) pyrazoles
The compounds of type (VI) have been prepared by the condensation
of  3-p-anisyl-5-hydrazino carbonyl pyrazole with different aromatic acid
chlorides in the presence of pyridine.
PART - VII : STUDIES ON  PYRAZOLYL PYRAZOLES
Compounds bearing pyrazole moiety are endowed with a variety of
biological activities such as hypnotic, antitubercular, amoebiciadal,
herbicidal, fungicidal, antiinflammatory, anticonvulsant, CNS depressant and










R = ArylType (VI)
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Anisyl-5-(α-methyl substitutedbenzalhydrazino
carbonyl) pyrazoles
The hydrazone derivatives of type (VII) have been prepared by
condensation of 3-p-anisyl-5-hydrazino carbonyl pyrazole with different
aromatic ketones in presence of catalytic amount of glacial acetic acid.
SECTION - II : Synthesis and therapeutic evaluation of 3-p-
Anisyl-5-(3'-aryl-4'-formyl pyrazol-1'-yl carbonyl)-
pyrazoles
The pyrazole derivatives of type (VIII) have been prepared by the



















R = ArylType (VIII)
PART - VIII : STUDIES ON NITRILES
Recently substituted nitrile derivatives have drawn considerable
attention due to their good pharmacological activities like cardiovascular,
herbicidal, sedative, antifungal and antibacterial. In order to achieving better
therapeutic activity, we have synthesised some novel nitriles bearing pyrazole
nucleus which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 3-p-
Anisyl-5-(α-cyano substituted benzylhydrazino
carbonyl)-pyrazoles
Nitr i le derivat ives of type (IX) have been synthesised by the
condensation of different aromatic aldehyde with 3-p-anisyl-5-hydrazino
carbonyl pyrazole by using potassium cyanide in presence of glacial acetic
acid at 0-5oC in stirring.
[B] STUDIES ON FURANS
Furan derivatives have been found to be associated with the interesting
bio log ica l  ac t iv i t ies  such as  ant i in f lammatory,  musc le  re laxants ,
antidepressant, antibacterial, antidiabetic, etc. These finding prompted us
to synthesis some furan derivatives possessing better therapeutic value which









R = ArylType (IX)
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PART - I : STUDIES ON CHALCONES
Chalcones are phenylstyryl ketones containing reactive keto-ethylenic
group (–C–CH=CH). Literature survey reveals that chalcone derivatives
possess germicidal, antimicrobial and antispasmodic activities. Hence it was
thought worthwhile to synthesise chalcone derivatives, which have been
described as under.
SECTION - I : Synthesis and therapeutic evaluation of 1-(p-
2'-Carboxyfuran-5'-yl phenyl)-3-aryl-2-propene-1-
ones
The chalcone derivatives of type (X) have been prepared by the
condensation of 5-p-acetophenyl furan-2-carboxylic acid with different aryl
aldehydes in presence of 40% NaOH.
PART - II : STUDIES ON ISOXAZOLES
Isoxazole plays a vital role owing to their of biological activities such
as hypnotic, sedative, antifungal and antibacterial, etc. In view of these facts,
it appeared of interest to design and synthesise isoxazole derivatives, which





R = ArylType (X)
9SECTION - I : Synthesis and therapeutic evaluation of 3-(p-
2'-Carboxyfuran-5'-yl phenyl)-5-aryl-isoxazoles
The isoxazole derivatives of type (XI) have been prepared by the
reaction of compounds of type (X) with anhydrous sodium acetate and
hydroxylamine hydrochloride in glacial acetic acid.
PART - III : STUDIES ON THIOPYRIMIDINES
Compounds bearing furan moiety are endowed with a variety of
biological activity such as antimicrobial, antitubercular, anticonvulsant and
anticancer etc. With observations, it was contemplated to synthesise some
thiopyrimidine derivatives which have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 2-Thio-
4-aryl-6-(p-2'-carboxyfuran-5'-yl phenyl)-1,2,3,4-
tetrahydropyrimidines
Thiopyrimidine derivatives of type (XII) have been synthesised by the
condensation of the  different chalcones of type (X) with thiourea in presence




R = ArylType (XI)







PART - IV : STUDIES ON BARBITONES
The emerging role of barbitones in pharmaceutical chemistry as well
as in biochemistry stimulated tremendous interest in the synthesis of
barbitones with therapeutic potential. They have been described as under.
SECTION - I : Synthesis and therapeutic evaluation of 5-(p-
2'-Carboxyfuran-5'-yl phenyl)-5-(1-aryl vinyl)
methino barbituric acids
Barbitone derivatives of type (XIII) have been prepared by the
condensation of chalcones of type (X) with barbituric acid in glacial acetic
acid.
The constitution of the synthesised products have been characterized
by using elemental analyses, infrared and 1H nucleus magnetic resonance










R = ArylType (XIII)
In vitro study on multiple biological activities has been carried out as
under:
(1) Selected compounds have evaluated for their in vitro biological assay
towards a strain of Mycobacterium tuberculosis H37 Rv at a
concentration of 6.25 µg/ml using Rifampin as standard drug, which
have been tes ted a t  Tubercu los i s  Ant imicrob ia l  Acquis t ion
Co-ordinatting Facility (TAACF), Alabama, U.S.A.
(2) All the newly synthesised compounds have been also evaluted for their
antibacterial activity towards Gram positive and Gram negative bacterial
strains and anti fungal act ivi ty towards Aspergillus niger  at
concentration of 40 µg/ml. The biological activity of the synthesised







It must be evident to even the most casual observer that medicine today
has entered upon an era of unprecedemted progress in the field of therapeutics,
due in large part of the development of new pharmaceuticals. Among the brilliant
scientific advances of this age-a list that includes aromatic fission, electronics and
aeronautics -a-foremost position showed undoubtedly be reserved for the growth
of modern drug therapy. It is too much to claim that the discoveries and inventions
in this sphere, merely in the last fifteen years, have contributed more to the
happiness, well-being, and health of humanity than has any other advancement.
The ward 'drug' is derived from the french word 'drogue' which means a dry
herb. According to 'WHO' a drug may be defined as "Any substance or product
which is used as intended to be used for modifying or exploring physiological
system or pathological status for the benefit of the recipient.''
Medicinal chemistry is important at the outset to note that drug discovery is
not an unambiguous term in the pharmaceutical R & D world. Medicinal chemistry
is mainly divided in two parts. The first, chemotherapy, treatment of infections,
parasits or maligant diseases by chemical agents, usually substances that shows
selective toxicity towards the pathogen. The other division relates to diseases of
bodily dysfunction and the agents employed are mainly compounds that effect
the functioning of enzymes, the transmission of nerve impulses or the action of
hormones on receptors.
Heterocyclic compounds are used for all these purposes because they have
a specific clinical reactivity, for example epoxides, aziridines and β-lactams,
because they resemble essential metabolites and can provide false synthons in
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biosynthetic processes, for example antimetabolites used in the treatment of cancer
and virus diseases, because they fit biological receptors and block their normal
working, or because they provide convenient building blocks to which biologically
active substituents can be attached. The introduction of heterocyclic groups into
drugs may affect their physical properties, for example the dissociation constants
of sulfa drugs, or modify their patterns of absorption, metabolism or toxicity.
During the period 1940 to 1960 a large number of important drugs have
been introduced and this period is regarded as "Golden period" of new drug
discovery. These are some of the specific examples representing new therapeutics.
Name of drug Year
1. Sulpha drugs 1933 The first antibacterial drug
2. Penicillin 1940 Antibiotic
3. Chloroquine 1945 Antimalarial
4. Methyldopa 1950 Antihypertensive
5. Chlorthiazide 1957 Diuretic
6. Adrenergic betablockers 1958 Coronary vasodilatory
7. Semi synthetic penicillins 1960 Antibacterial
8. Trimethoprim 1965 Antimicrobial
9. Disodium chromoglycoate 1967 Antiallergic
AIMS AND OBJECTIVES
In the pharmaceutical field, there has always been and will continue to be
a need for new and novel chemical inhibition of biological fraction. Our efforts
are focused on the introduction of chemical diversity in the molecular frame work
in order to synthesizing pharmacologically interesting compounds of widely
different composition.
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During the course of research work, looking to the applications of the
heterocyclic compounds, several entities have been designed, generated and
characterised using spectral studies. The details are as under.
* To generate several derivatives like azomethines, oxadiazoles, imidazolines,
pyrazolones, sulphonamides, arylamides, pyrazoles, nitri les bearing
3-p-anisyl pyrazol-5-carboxy acid hydrazide.
* To synthesise chalcones, isoxazoles, thiopyrimidines and barbitones bearing
5-p-acetophenyl furan 2-carboxylic acid.
* To characterise these products for structure elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
* To cheak the purity of all compounds using thin layer chromatography.
* To evaluate these new products for better drug potential against different
strains of bacteria and fungi.
* Selected compounds have been sent to "Tuberculosis Antimicrobial
Acquisition and Co-ordinating Facility" (TAACF), Southern Research






The pyrazole ring system (I) consists of a dobly unsaturated five membered
ring containing two adjacent nitrogen atoms. Knorr1,2 first synthesised a
compound containing this system in 1883 by the reaction of ethylacetoacetate
with phenyl hydrazine which yield 1-phenyl-3-methyl-5-pyrazolone (II).
Knorr3 introduced the name pyrazole for these compounds to donate that
the nucleus derived from pyrrole by replacement of carbon by nitrogen; since
many drugs and dyes contain the pyrazole nucleus, the class has been widely
studied and the field continuous to be active today even though antipyrine and
related medicine no longer in common use. Pyrazolone dyes are especially
important in colour photography.
SYNTHETIC ASPECT
Several methods for the preparation of pyrazoles are narrated in literature.
1. The reaction of hydrazine or its derivatives such as alkyl or aryl hydrazines,
















2. R.  M.  Sa leh4 have prepared pyrazo le  by cyc l i za t ion of  e thy l -2-
thenoylpyruvate with hydrazine hydrate.
3. The reaction of hydrazine with α,β-unsaturated carbonyl compounds.
4. The reaction of aliphatic diazo compounds such as diazomethane or
diazoester with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic values
of pyrazole moiety since their discovery. A large number of substituted pyrazole



































W. Kutsuaki and co-worker19 have prepared pyrazoles and reported their
nimeticidal activity. R. Y. Huang and co-worker20 have prepared some 1,2,4-
triaryl-4-alkyl-pyrazoles as estrogen receptor. C. Vittoria et al.21 have prepared
pyrazoles as adenosine receptor antagonist. Edima Akio et al.22 have synthesised
pyrazole derivatives as antitumor agents (III).
David L. Selwood and co-worker23 have prepared pyrazole derivatives as
activators of the nitric oxide receptor. Bebbington David et al.24 have synthesised
pyrazoles as protein kinase inhibitors. Volk Thorsten et al.25 have prepared
pyrazoles and reported their herbicidal activity. Gellibert and co-worker26 have
prepared pyrazole derivatives and shown them as TGF-B inhibitors. Berta Daniela
et al.27 have synthesised pyrazoles useful as anticancer, antiproliferative, antiviral
























Pascal Rathelst et al.28 have synthesised pyrazoles as antiparastic agent (V).
Brown D. L. et al.29 have synthesised pyrazole derivatives useful as treatment of
cyclooxygenase-2-medicated disorders such as inflammation. Nishimura
Tsoshihiro et al.30 have prepared pyrazoles as inhibitors of human SGLT2. Hirai
Kenji et al.31 have prepared pyrazole derivatives and documented herbicidal
activity. Adnan A. Bekhil et al.32 have synthesised pyrazoles (VI) and studied
their antiinflammatory and antimicrobial activity.
Okada I tara et  a l .33 have synthesised and reported pyrazoles as
agrochemical fungicides. Dymock et al.34 have prepared pyrazole derivatives as
HIV reverse transcriptase inhibitors. Some, pyrazoles are found to possess
anticancer35, herbicidal36,37, 5-HT20 receptor
38, nicotinic acid receptor39,
neuropeptide Ts receptor antagonist40, Cox-II inhibitor41, glycine transporter
protein inhibitor42 and antibacterial activities43.
[A] STUDIES ON PYRAZOLES
PART - I : STUDIES ON AZOMETHINES
PART - II : STUDIES ON OXADIAZOLYL PYRAZOLES
PART - III : STUDIES ON IMIDAZOLINYL PYRAZOLES
















PART - V : STUDIES ON  SULPHONAMIDES
PART - VI : STUDIES ON  ARYLAMIDES
PART - VII : STUDIES ON  PYRZOLYL PYRAZOLES






A zometh ine  der iva t ives  have been found to  be  potent  drug in
pharmaceutical industries and possess a wide spectrum of biological activity.
Azomethines are also known as Schiff base and they are well known intermediate
for the preparation of azetidinone, thiazolidinone, formazon, arylacetamide and
many other derivatives. These are the compounds contain characteristic -C=N
group.
Azomethines are obtained mainly by warming the aldehyde & aromatic
amine together. However, it is sometimes more convenient to work in a solvent
such as alcohol, dilute acetic acid or glacial aceticacid. Sometimes the reaction is
aided by trace of acid; in other cases the hydrochloride of the amines can be
used in the synthesis. In general Schiff bases do not react further with either of
the reagents used in their preparation, as do most of the other types of simple
intermediates.
SYNTHETIC ASPECT
1. General account of the summary of reaction of aldehydes with amines
(aromatic or aliphatic) has been reviewed by Murray.44
R – CHO + R' – NH
2
R – CH = N – R'
2. Strache45 and Van Alphen46 have prepared imine involves in two steps.
(I). Addition of the amine to the carbonyl group of the aldehyde gives aldol.
The aldol is rarely capable of isolation.
R – CHO + R' – NH
2
R - CHOHNH – R'
Azomethines... 20
(II). The loss of water to give an imine (azomethine), this corresponds to the
"crotonaldehyde stage" of the aldol condensation.
R – CHOHNH – R' R – CH = N – R' + H
2
O
3. Oddo & Tognacchini47 have introduced the comparative rates of  formation
of Schiff base from aniline, substituted amine & aromatic aldehyde using a
cryscopic method follow the course of reaction.
THERAPEUTIC IMPORTANCE
Smalders  e t  a l .48 have documented some new azomethines l ike
benzylidenenaphthylamine (I) reacts with HP(O) (OCH2CH2Cl)2 to give potential
antitumor reagent phosphates (II).
Yadawe M. S. and Patil S. A.49 have prepared azomethines. Some of the
little compounds were screened for their antibacterial and antifungal activities in
compound (III). Mehta R. H. et al.50 have prepaerd coumarin azomethine


























Khalafallah A. K. and Hassan M. E.51 have suggested some styryl Schiff
bases spiro derivatives as potential antibacterial and antifungal activity.
Chohan et al.52 have reported azomethine of type (V) these Schiff bases have
been screened and compared for their antibacterial action against bacterial species
E. Coli, Pesudomonus aeruginoose and Klebisella Pneumoniase.
Deshmukh M. D. and Doshi A. G.53 have synthesised some new
azomethines show good antimicrobial activity against test organism. Wang,
Yangang and co-workers54 have screened some azomethines having good plant
hormone ac t iv i ty.  Das  e t  a l .55  have prepared Sch i f f  base  o f
aminohydroxyguanidine (SB-AHGs) were tested for antiviral activity against
herpes simplex virus type-1 (HSV-1) and adenovirus type-5 (Ad5) alone with 11
other heterocyclic SB-AHGs. Some compounds had good antiadenoviaral
ac t iv i ty.  Solankee Anjani  e t  a l .56 have sugges ted addi t ion of  3 ,4,5-
trimethoxybenzaldehyde to 4-thiazolidinones resulted in benzylidine derivatives
having potential antibacterial activity. Ram, Tilak et al.57 have synthesised some
Schiff bases, thiazolidinones ∆2-triazolines and formazons of 2-chloropheno
thiazines screened against corrageenin induced edema in albino rats. The
thiazolidinones showed promising antiinflammatory activity.
Cascaval Alexandru et al.58 have synthesised azomethine of type (VI) as




X = O, S













Omar and et al.59 have determined cyclocondensation of azomethines
having good antischistosomal activity. Pawar R. P. et al.60 have synthesised
azomethines by the condensation of iodovanillin with different substituted
aromatic amines. Holla B. S. et al.61 have documented azomethines having
triazole moiety and possess good antibacterial activity. Ergenc and co-workers62
have synthesised azomethines having antifungal activity.
B. Shivarama Holla et al.63 have prepared azomethines which found to
possess antibacterial and antiinflammatory activity. Pascal Rathelst et al.64 have
prepared some new azomethines and reported them as antiparastic agents. Adnan
A. Bekhil et al.65 studied the antiinflammatory activities of some azomethines.
Dimmock J. R. et al.66 have reported azomethines having cytotoxic agent.
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh and co-worker67,68 have prepared azomethines and studied
their antimicrobial activity. A. R. Parikh and co-worker have prepared azomethines
having quinoline moiety.69
Thus with an effort to capitalize the biological potential of the heterocyclic
system and to provide more interesting compounds for biological screening, we
have under taken the synthesis of azomethines bearing pyrazole moiety.





SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-
SUBSTITUTED BENZALHYDRAZINOCARBONYL PYRAZOLES
The growing potent literature of recent years demonstrates that the Schiff
bases are used as better therapeutic agents. In view of this findings, it appeared
of interest to synthesise Schiff bases of the type (I) by the condensation of
3-p-anisyl-5-hydrazinocarbonyl pyrazole with various aromatic aldehydes in order
to study their biodynamic behaviour, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = p-Anisyl = 350, m/z = 351 (m+1).
The products have been screened for their in vitro biological activity like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37 Rv
at a concentration of 6.25 µg using Rifampin as a standard drug, antibacterial
activities towards Gram positive and Gram negative bacterial strains and antifungal
activity towards Aspergillus niger at a concentration of 40 µg. The biological
activities of the synthesised compounds were compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known antibiotics recorded on page 37. The details have been cited in
Part (I), Section - I (D).













































IR SPECTRAL STUDY OF 3-p-ANISYL-5-(p-METHOXYBENZALHYDRAZINO
CARBONYL) PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2958 2975-2950 549
-CH3 C-H str. (sym.) 2873 2880-2860 "
C-H def. (asym.) 1456 1470-1435 "
C-H def. (sym.) 1382 1385-1370 "
Aromatic C-H str. 3072 3080-3030 550
C=C str. 1571 1585-1570 "
1504 1520-1480 "
C-H i.p. def. 1110 1125-1090 "
1002 1070-1000 "
C-H o.o.p. def. 839 835-810 "
Pyrazole N-H str. 3317 3550-3250 549
moiety C=O str. 1654 1680-1630 "
N-H def. 1571 1650-1580 "
(overlapped)
C-O-C str. (sym.) 1253 1275-1200 "
C-O-C str. (asym.) 1028 1075-1020 "
























PMR SPECTRAL STUDY OF 3-p-ANISYL-5- (p -METHOXYBENZAL
HYDRAZINOCARBONYL) PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.62 - 3Hx2 singlet Ar-OCH3x2
2 6.89 Jba=9 2H doublet Ar-H b,b'
3 6.95 Jab=9 2H doublet Ar-H a,a'
4 7.06 - 1H singlet -N=CHe
5 7.65 - 1H singlet Ar-Hf
6 7.67 Jcd=3 2H doublet Ar-Hc,c'
7 7.70 Jdc=3 2H doublet Ar-Hd,d'
8 8.34 - 1H singlet -NH






























































































































































Gram positive bacteria : Staphylococcus aureus,
Bacillus megaterium
Gram negative bacteria : Proteus vulgaris,
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40 µg
Solvent : Dimethyl formamide





The antimicrobial activity was compared with standard drugs viz. Ampicillin,
Amoxicillin, Norfloxacin, Penicillin and antifungal activity was compared with
viz. Greseofulvin, the zones of inhibition have been measured in mm.
Antitubercular Activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF), U.S.A.
Method : BACTEC 460 Radiometric system
Bacteria : Mycobacterium tuberculosis H37 Rv
Concentration : 6.25 µg/ml
Standard drug : Rifampin
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-
SUBSTITUTED BENZALHYDRAZINOCARBONYL PYRAZOLES
[A] Synthesis of Ethyl-p-anisylpyruvate
A mixture of p-Methoxyacetophenone (1.50 g, 0.01 M) and diethyl oxalate
(1.46 g, 0.01 M) in 50 ml sodium methoxide solution was warmed for 5 min.,
cooled and the separated solid washed with dil. hydrochloric acid and crystallised
from ethanol. Yield 88% (2.2g), m.p. 138oC (C13H14O5; Required: C, 62.04;
H, 5.06; Found: C, 61.91; H, 5.10%). TLC solvent system : Acetone : Benzene
(0.5 : 9.5).
[B] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
A mixture of Ethyl-p-anisylpyruvate (2.50 g, 0.01 M) and hydrazine hydrate
(1 ml, 0.02 M) in ethanol (50 ml) was refluxed for 6 hrs. and cooled. The solid,
thus separated, was crystallised from ethanol. Yield 74% (1.7g), m.p. 204oC
(C11H12O2N4; Required: C, 56.89; H, 5.17; N, 24.13 ; Found: C, 56.97; H,
5.12; N, 24.08%). TLC solvent system : Acetone : Benzene (2.5 : 7.5).
[C] Synthesis of 3-p-Anisyl-5-(p-methoxybenzalhydrazinocarbonyl)
pyrazole
A mixture of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole (2.32 g, 0.01 M) and
4-methoxybenzaldehyde (1.36 g, 0.01 M) was refluxed on methanol for 7 hrs.
The contents were poured into crushed ice and filtered. The isolated product
was crystallised from ethanol. Yield 69% (2.4g), m.p. 228oC (C19H18O3N4;
Required: C, 65.14; H, 5.14; N, 16.00 ; Found: C, 65.21; H, 5.09; N, 15.96%).
TLC solvent system : Acetone : Benzene (4 : 6).
Similarly other schiff bases have been synthesised. The physical data are
recorded in Table No. 1.
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[D] Antimicrobial activity of 3-p-Anisyl-5-substituted benzalhydrazino
carbonyl pyrazoles
All the products have been evaluated for antimicrobial activity described
as under.
(a) Antimicrobial activity
It was carried out by cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method, was inoculated aseptically
with 0.5 ml of 24 hrs. old subculture of B. megaterium, S. aureus, E. coli
and P. vulgaris in separate conical flasks at 40-50oC and mixed well by gentle
shaking. About 25 ml content of the flask were poured and evenly spreaded in a
petridish (13 cm in diameter) and allowed to set for 2 hrs. The cups (10 mm in
diameter) were formed by the help of borar in agar medium and filled with 0.04
ml (40 µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 mol of DMF in a similar manner and the zones of inhibition
of bacterial growth were measured in millimeter and are recorded in Graphical
Chart No. 1.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Sabouraud's agar slants. Sterilised Sabouraud's
agar medium was inoculated with 72 hrs. Old 0.5 ml suspension of fungal spores
in a separate flask. About 25 ml of the inoculated medium was evenly spreaded
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in a petridish and allowed to set for two hrs. The plates were incubated at 30oC
for 48 hrs. After the completion of incubation period, the zones of inhibition of
growth in the form of diameter in mm was measured. Along the test solution in
each petridish one cup was filled with solvent which act as control. The zones of
inhibition are recorded in Graphical Chart No. 1.
(b) Antitubercular activity
The antitubercular evaluation of compounds was carried out at Tuberculosis
Antimicrobial Acquisition and Co-ordination Facility (TAACF), U.S.A. primary
screening of the compounds for antitubercular activity have been conducted at
6.25 µg/ml towards Mycobacterium Tuberculosis H37 Rv in BACTEC 12B
medium using the BACTEC 460 rediometr ic  sys tem. The compounds
demonstrating atleast >90% inhibition in the primary screen have been retested
at lower concentration towards Mycobacterium Tuberculosis H37 Rv to
determine the actual minimum inhibitory concentration (MIC) in the BACTEC
460.
The antitubercular activity data have been compared with standard drug,
rifampin at 0.25 µg/ml concentration and it showed 98% inhibition. The data for
















1a C6H5- C18H16O2N4 320 272 0.65 73 17.48 17.42
1b 4-OCH3-C6H4- C19H18O3N4 350 228 0.69 69 16.00 15.96
1c 2-Cl-C6H4- C18H15O2N4Cl 354.5 234 0.62 70 15.80 15.73
1d 4-Cl-C6H4- C18H15O2N4Cl 354.5 110 0.65 75 15.80 15.75
1e 3,4-(OCH3)2-C6H3- C20H20O4N4 380 186 0.54 68 14.74 14.68
1f 2-OH-C6H4- C18H16O3N4 336 198 0.58 83 16.67 16.62
1g 4-OH-C6H4- C18H16O3N4 336 224 0.60 63 16.67 16.59
1h 4-OH-3-OCH3-C6H3- C19H18O4N4 366 165 0.59 74 15.30 15.23
1i -CH=CH-C6H5- C20H18O2N4 346 128 0.54 69 16.18 16.11
1j 2-NO2-C6H4- C18H15O4N5 365 160 0.69 74 19.17 19.12
1k 3-NO2-C6H4- C18H15O4N5 365 156 0.62 71 19.17 19.10
1l α-C4H3O- C16H14O3N4 310 486 0.54 66 18.06 18.01
1m 3-OC6H5-C6H4- C24H20O3N4 412 228 0.57 62 13.59 13.52
1n 2-Cl-6-OCH3-C9H4N- C22H18O3N5Cl 435 167 0.63 65 16.07 15.99







































B. mega 17 14 15 18 11 18 22 17 14 20 17 12 15 17 23 22 2
S.aureus 17 12 13 15 14 11 12 21 14 15 13 11 11 12 22 23 1
P.vulgaris 13 12 11 12 15 18 16 11 13 16 17 14 15 13 15 18 1
E.coli 13 15 19 18 17 11 12 13 21 13 13 14 16 12 21 21 2
A.niger 19 17 16 15 20 19 19 18 22 17 19 23 18 16 0 0 0








COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-I
Section - I : Antimicrobial activity of 3-p-Anisyl-5-substituted benzalhydrazinocarbonyl pyrazoles
1g  (22) 1a (17) 1c (19) 1e (15) 1i (22)
1j  (20) 1h  (21) 1d (18) 1f (18) 1l (23)
1i (21) 1k (17)
1m (15)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TABLE NO.-1a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
161989 AB-4 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 59
161994 AB-9 -CH=CH-C6H5 Sau.uni Alamar H37Rv >6.25 54  ''
161998 AB-13 2-Cl-6-OCH3-C6H4N Sau.uni Alamar H37Rv >6.25 43  ''
161992 AB-7 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 42  ''
161988 AB-3 2-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 26  ''
161995 AB-10 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 23  ''
161986 AB-1 C6H5- Sau.uni Alamar H37Rv >6.25 22  ''
161990 AB-5 α-C4H3O- Sau.uni Alamar H37Rv >6.25 10  ''
161987 AB-2 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 5  ''
161991 AB-6 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 2  ''
161993 AB-8 4-OH-3-OCH3-C6H3- Sau.uni Alamar H37Rv >6.25 0  ''
161996 AB-11 2-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
161997 AB-12 3-OC6H5-C6H4 Sau. uni. Alamar H37Rv >6.25 0 "
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.025mg/ml














Thermally, stable neutral aromatic molecule 1,3,4-oxadiazoles71 have been
known for about 80 years. They have been subject of intensive investigation
particularly in the last decade because of their broad spectrum of uses as
biologically active compounds in medicine, agriculture and dyestuff industries.
1,3,4-Oxadiazoles also have been useful in diverse areas like drug synthesis,
hert resistant and UV absorbing polymers. The literature for the chemistry of 1,3,4-
oxadiazole is available in the review prior to 196572-75.
SYNTHETIC ASPECT
Most of 1,3,4-oxadiazoles are best obtained by synthesising from acyclic
precursors. Such reactions are mainly 'one-bond' or 'two-bond' cyclisation.
Different methods for the synthesis have been cited in literature76-85.
THERAPEUTIC IMPORTANCE
The therapeutic activities shown by the 2-5-disubstituted 1,3,4-oxadiazoles














Antibacterial activity of oxadiazoles is documented by B. Holla.94 J. C. S.
Kataky95 have reported 1,3,4-oxadiazoles and evaluated for antimicrobial activity
and fungitoxicity. Harendra Singh et al.96 have synthesised 1,3,4-oxadiazoles
and screened for fungitoxicity. Cao et al.97 have reported insecticidal activity of
oxadiazole derivatives.
Antiinflammatory activity of 1,3,4-oxadiazole derivatives (II) is documented
by Shalabh Sharma et al.98
C. W. Nagor and co-worker99 have reported 1,3,4-oxadiazoles (III) as orexin
receptor antagonists.
Ibrahim P. et al.100 demonstrated some 1,2,4-oxadiazole derivatives and
useful for cardiovascular disease and diabetes. V. W. Bradford et al.101 have
synthesised oxadiazoles use as metabotropic glutamate receptor antagonists for
inhibiting neuronal damage. Some of the oxadiazoles have been patented for
























CONTRIBUTION FROM OUR LABORATORY
Parikh et al. have synthesised variety105 of 1,3,4-oxadiazoles bearing aryl
sulphonamido106,107, mercapto108, quinolinyl109 and amino moieties at 2-
position (Y) and 4'-pyridyl, benzene sulphonamidophenyl, diiodoquinolinoxy
and aryl sulphonamidophenyl at 5-position (X) as antimicrobial agents.
H. H. Parekh and co-workers have investigated 1,3,4-oxadiazoles having
tr iaz ine110,111,  phenyl  su lphonyl112,  2 ' - i sopropyl -5-methylphenoxy
methyl113-115, depson116-119 moieties at 5-position (X) and aryl, arylamino,
arylsulphonamido, substituted benzalamino moieties at 2-position (Y) and
evaluated their antimicrobial activity.
General structure for above references is as under.
Moreover, H. H. Parekh et al.120,121 have formulated some new
oxadiazoles as biologically active agents. H. H. Parekh et al.122 have synthesised
2,5-disubstituted 1,3,4-oxadiazoles as biologically active heterocycles. A. R.
Parikh et al.123 have synthesised 2-aryl-3-(2'-mercapto-1',3',4'-oxadiazol-5'-yl-
phenyl-4-thiazolidinones).
Thus with an effort to capitalize the biological potential of the heterocyclic
system and to provide more interesting compounds for biological screening, we
have under taken the synthesis of several oxadiazoles which has been described
as under.







NX = , SO2NH ,
SO2NH.R(IV)
Y =NH–SO2–R,    Aryl,   –SH,   –NH2,  –NHCO – R,  –N = CH – R
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(5'-
ARYL-1',3',4'-OXADIAZOL-2'-YL) PYRAZOLES
Synthesis of 1,3,4-oxadiazole derivatives has attracted considerable attention
in view of therapeutic applications. Looking to this, the synthesis of 1,3,4-
oxadiazoles of type (II) was undertaken by the condensation of different aromatic
acid with 3-p-anisyl-5-hydrazinocarbonyl pyrazole in presence of phosphorous
oxychloride, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = 3,4 Dimethoxyphenyl = 378,
m/z  = 379 (m+1).
The products have been screened for their in vitro biological activity like
antitubercular activity towards a strain of Mycobacterium tuberculosis
H37 Rv at a concentration of 6.25 µg using Rifampin as a standard drug,
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 51. The details
have been cited in Part (I), Section - I (D).
















IR SPECTRAL STUDY OF 3-p-ANISYL-5-(5'-PHENYL-1',3',4'-OXADIAZOL-2'-YL)
PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2958 2975-2950 549
-CH3 C-H str. (sym.) 2837 2880-2860 "
C-H def. (asym.) 1442 1470-1435 "
C-H def. (sym.) 1377 1385-1370 "
Aromatic C-H str. 3049 3080-3030 550
C=C str. 1537 1585-1570 "
1494 1520-1480 "
C-H i.p. def. 1126 1125-1090 "
1055 1070-1000 "
C-H o.o.p. def. 825 835-810 "
Pyrazole C=N str. 1602 1650-1600 554
moiety C-N str. 1307 1340-1250 549
C-O-C str. (sym.) 1245 1275-1200 "
C-O-C str. (asym.) 1026 1075-1020 "

























PMR SPECTRAL STUDY OF 3-p-ANISYL-5-(5'-PHENYL-1',3',4'-OXADIAZOL-2'-YL)
PYRAZOLE
Internal Standard : TMS
Solvent : DMSOd6
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.77 - 3H singlet Ar-OCH3
2 7.04 Jba=6 2H doublet Ar-H b,b'
3 7.11 Jab=6 2H doublet Ar-Ha,a'
4 7.45 Jde=6 3H doublet Ar-H d,e,f
Jef=6
5 7.71 Jgf=6 1H doublet Ar-Hg
- 1H singlet Ar-Hh
6 7.77 Jcd=6 1H doublet Ar-Hc
























































































































m/z = 378 
m/z = 348 
m/z = 364 
m/z = 278 
m/z = 231 
m/z = 192 
m/z = 164 
m/z = 148 
m/z = 120 
m/z = 215 
m/z = 108 
m/z = 318 


























SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(5'-
ARYL-1',3',4'-OXADIAZOL-2'-YL) PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 3-p-Anisyl-5-(5'-phenyl-1',3',4'-oxadiazol-2'-yl) pyrazole
Mixture of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole (2.32 g, 0.01 M) and
benzoic acid (1.21 g, 0.01 M) in phosphorous oxychloride (5 ml) was refluxed
for 6 hrs. The content were cooled and poured onto crushed ice. It was neutrilised
with sodium bicarbonate solution and resulting solid was filtered, dried and
crystall ised from ethanol. Yield 80%(2.5g), m.p. 201oC (C18H14O2N4;
Required: C, 67.92; H, 4.40; N, 17.61 ; Found: C, 67.99; H, 4.58; N, 17.56%).
TLC solvent system: Acetone : Benzene (2 : 8).
Similarly, other different aromatic acids were condensed. The physical data
are recorded in Table No. 2.
[C] Antimicrobial activity of 3-p-Anisyl-5-(5'-aryl-1',3',4'-oxadiazol-2'-
yl) pyrazoles
Antimicrobial testing was carried out as described in Part - I. Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 2.
The antitubercular activity of the compounds of type (II) was carried out by
TAACF, the Southern Research Institute, U.S.A. as described in Part - I, Section - I (D)
















2a C6H5- C18H14O2N4 318 201 0.64 80 17.61 17.56
2b 3-OCH3-C6H4- C19H16O3N4 348 >270 0.67 68 16.09 16.05
2c 4-OCH3-C6H4- C19H16O3N4 348 190 0.78 79 16.09 16.02
2d 2-OH-C6H4- C18H14O3N4 334 196 0.86 81 16.77 16.69
2e 4-OH-C6H4- C18H14O3N4 334 229 0.80 86 16.77 16.71
2f 2,4-(OH)2-C6H3- C18H14O4N4 350 207 0.65 82 16.00 16.97
2g 2-CH3-C6H4- C19H16O2N4 332 120 0.58 74 16.87 16.79
2h 3-CH3-C6H4- C19H16O2N4 332 129 0.48 83 16.87 16.81
2i 3,4-(OCH3)2-C6H3- C20H18O4N4 378 157 0.58 84 14.81 14.76
2j 2-Cl-C6H4- C18H13O2N4Cl 382 193 0.61 84 14.64 14.59
2k 4-Cl-C6H4- C18H13O2N4Cl 382 208 0.78 61 14.64 14.58
2l -CH=CH-C6H5 C20H16O2N4 344 148 0.80 84 16.27 16.21
2m α-C5H4N- C17H13O2N5 319 171 0.82 76 21.94 21.88
2n 4-NH2-C6H4- C18H15O2N5 333 209 0.48 72 21.02 20.95
2o 2-NO2-C6H4- C18H13O4N5 363 157 0.59 65 19.28 19.23







































B. mega 18 11 14 18 20 21 11 11 12 15 18 17 12 13 14 23 22 2
S.aureus 13 11 16 22 12 15 17 16 14 13 14 15 13 12 16 22 23 1
P.vulgaris 16 12 12 13 11 13 12 17 14 13 12 11 11 12 14 15 18 1
E.coli 18 12 15 17 16 13 13 14 12 16 21 17 11 15 18 21 21 2
A.niger 18 17 16 19 15 13 17 21 19 20 21 19 17 15 12 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-II
Section - I : Antimicrobial activity of 3-p-Anisyl-5-(5'-aryl-1',3',4'-oxadiazol-2'-yl)pyrazoles
2e (20) 2d (22) 2a (18) 2a (16) 2h (21)
2f (21) 2g (17) 2k (21) 2h (17) 2j (20)
2o (18) 2k (21)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TABLE NO. 2a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
162000 AB-15 3-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 88
162006 AB-21 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 70  ''
162011 AB-26 2-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 66  ''
162009 AB-24 α-C5H4N- Sau.uni Alamar H37Rv >6.25 50  ''
162013 AB-28 3,4-(OCH3)2-C6H3- Sau.uni Alamar H37Rv >6.25 46  ''
162012 AB-27 3-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 27  ''
162003 AB-18 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 22  ''
161999 AB-14 C6H5- Sau.uni Alamar H37Rv >6.25 20  ''
162007 AB-22 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 13  ''
162001 AB-16 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162002 AB-17 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162004 AB-19 3-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162005 AB-20 4-NH2-C6H4- Sau. uni. Alamar H37Rv >6.25 0 "
162010 AB-25 -CH=CH-C6H5 Sau. uni. Alamar H37Rv >6.25 0 "
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.025mg/ml














Imidazolinone, a five membered heterocycle having 2-nitrogen atoms at
the 1 and 3-positions and -C=O group at following positions : 2-oxo-imidazoline
(I). 4-oxo-imidazoline (II), 5-oxo-imidazoline (III).
The discovery of the 2-substituted-5-imidazolines dates back to the year
1888, when A. W. Hoffmann124 for the first time discovered 5-oxo-imidazoline
by heating N1-diacetylethylene diamine in a stream of dry hydrogen chloride
and moreover the same compound was prepared by A. Ladenburg125 by the
fus ion of  two equiva lents  o f  sodium aceta te  wi th  one equiva lent  o f
ethylenediamine dihydrochloride.
SYNTHETIC ASPECT
Synthesis of imidazolinone have been reported by several methods in
literature126,127. Aminolysis of oxazolone with amines led to the formation of
imidazolinones which has been reported in literature.128
REACTION MECHANISM
Reaction of azalactone with various compounds such as water, alcohols,
amines and hydrogen halides, amides of α-acylaminoacryclic acids obtained from
the condensation of azalactone and primary amine can be converted into



























Under various conditions the ring closure can be effected, imidazolinone
derivatives have been synthesised with the conversion of substituted anilides by
the action of phosphorus oxychloride.
THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc are various
imidazolinone derivatives which have been used as adrenergic stimulants and
tolazoline and phentolamine as adrenergic blocking agents. Various imidazolinones











Peter and co-workers145 have prepared substituted imidazolinones which
inhibited the abnormal cell growth in human body. Biplab De et al.146 have
reported some new 5-oxo-imidazolines as antimicrobial agents, imidazolinones




















R' = NH2, Dry C5H5N / Abs. C2H5OH, K2CO3
Imidazolinyl pyrazoles... 54
Stefan A. Lauter and co-workers149 have isolated imidazolines from different
methods and tested for the treatment of cytokine release. Battistina et al.150 have
demonstrated some novel imidazolines to possess insecticidal activity. Imidazoline
derivatives have been prepared by Declerca Arthur and co-workers151 showing
anti-HIV activity. Ding, Ming-Wu et al.152 have prepared novel imidazolines and
reported their antifungal activity.
Prasanna A. Datar et al.153 have synthesised some new imidazolinones (IV)
and reported as potent anticancer agent.
Irene M. Lagoja et al.154 have synthesised some novel imidazolines and
reported their anti reteroviral activity. Jean-Michel H. et al.155 have demonstrated
imidazolines to possess antileishmanial activity.
CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh et al. have synthesised imidazolinones bearing phthalazine156,
L-base of chloromphenicol157, benzylamino and amino158 moiety at one
position which were evaluated for their antimicrobial activity. H. H. Parekh and
co-workers have assessed imidazolinones containing isoniazide159 and s-










R = -CH3, -CH2-CH3, -m-NO2-C6H4
Imidazolinyl pyrazoles... 55
General structure for above references is as under.
H. H. Parekh et al.161 have reported several novel imidazolines bearing
benzimidazole moiety which were evaluated for their ability to potentiate
antimicrobial activity. Parikh et al.162 have reported 4-(4'-arylidene-2'-phenyl-
5'-oxo-imidazoline-1'-yl)-benzophenones which were screened for their
antimicrobial activity.
Moreover, A. R. Parikh, H. H. Parekh have synthesised the newer-5-oxo-




































Y = CH3 / C6H5,     Z = H,     R = Aryl
Imidazolinyl pyrazoles... 56
* Synthesis and biological screening of some novel 5-oxo-imidazolines163.
* 2-chloro-8-methylquinol ine-3-y l -N-(2 ' -phenyl-4 ' -ary l idene-5 ' -oxo-
imidazolin164-1yl) azomethanes.
* Synthesis and biological activity of some imidazoline165 derivatives.
* Synthesis and biological evaluation of 5-oxo-imidazolines166.
A. R. Parikh et al.167 have prepared imidazolines and studied their
antimicrobial activity. H. H. Parekh and co-workers168 have documented
imidazolines possess anticancer and antitubercular activity.
With a view to getting better therapeutic agent, it was contemplated to
synthesise imidazolinone with pyrazole as a parent molecule, to enhance the
overall activity of resulting compounds which have been described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-p-ANISYL-5-(2'-PHENYL-4'-ARYLIDENE-5'-OXO-




SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(2'-
PHENYL-4'-ARYLIDENE-5'-OXO-IMIDAZOLIN-1'-YL AMINOCARBONYL)
PYRAZOLES
Imidazolinones derivatives represent one of the most active classes of
compounds having a wide spectrum of biological activities with an aim to getting
better therapeutic agent the preparation of 5-oxo imidazoline of type (III) have
been undertaken by the condensation of 3-p-anisyl-5-hydrazinocarbonyl pyrazole
with substituted azalactones, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = o-Hydroxyphenyl = 479,m/z = 479.
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 68. The details
have been cited in Part (I), Section - I (D).
































R CHO + HOOC NH
COC6H5
R = ArylType (III)
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IR SPECTRAL STUDY OF 3-p-ANISYL-5-[2'-PHENYL-4'-(p-CHLOROBENZILIDENE)-5'-
OXO-IMIDAZOLIN-1'-YL AMINOCARBONYL] PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2960 2975-2950 549
-CH3 C-H str. (sym.) 2850 2880-2860 "
C-H def. (asym.) 1454 1470-1435 "
C-H def. (sym.) 1361 1385-1370 "
Aromatic C-H str. 3066 3080-3030 550
C=C str. 1535 1585-1570 "
1487 1520-1480 "
C-H i.p. def. 1114 1125-1090 "
1066 1070-1000 "
C-H o.o.p. def. 829 835-810 "
Pyrazole N-H str. 3365 3550-3250 549
moiety C=O str. 1666 1680-1630 "
C-O-C str. (sym.) 1255 1275-1200 "
C-O-C str. (asym.) 1026 1075-1020 "
Imidazoli- C=O str. 1710 1760-1655 "
none C=N 1602 1640-1555 "







































PMR SPECTRAL STUDY OF 3-p-ANISYL-5-[2'-PHENYL-4'-(p-METHOXYBENZILIDENE)
5'-OXO-IMIDAZOLIN-1'-YL AMINOCARBONYL] PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.88 - 3H singlet Ar-OCH3
2 3.89 - 3H singlet Ar-OCH3
3 7.01 Jba=9 2H doublet Ar-Hb,b'
4 7.07 Jcd=9 2H doublet Ar-H c,c'
5 7.35 Jdc=6 2H doublet Ar-Hd,d'
6 7.47 Jkj=9 1H doublet Ar-Hk
7 7.54 - 1H singlet Ar-He
8 7.60 Jab=6 2H doublet Ar-H a,a'
9 7.62 - 1H singlet Ar-Hj
10 7.64 - 1H singlet -NH
11 7.72 - 3H triplet Ar-H g,h,i
12 8.07 - 1H singlet =CHf



































































































































m/z = 479 
m/z = 469 
m/z = 442 
m/z = 426 
m/z = 407 
m/z = 389 
m/z = 373 m/z = 236 
m/z = 223 m/z = 215 m/z = 206 m/z = 178 
m/z = 162 
m/z = 146 
m/z = 106 
m/z = 120 











































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(2'-
PHENYL-4'-ARYLIDENE-5'-OXO-IMIDAZOLIN-1'-YL AMINOCARBONYL)
PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 4-Arylidene-2-phenyl-5-oxazolinones169
These were synthesised by the condensation of substituted benzaldehyde
with benzoyl glycine in presence of sodium acetate and acetic anhydride, as
described by vogel.
[C] Synthesis of 3-p-Anisyl-5-(2'-phenyl-4'-methoxybenzilidine-5'-oxo-
imidazolin-1'-yl aminocarbonyl) pyrazole
Mixture of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole (2.32 g, 0.01 M) and
2-phenyl-4-(4'-methoxybenzilidine)-5-oxazolinone (2.53 g, 0.01 M) 20 ml of dry
pyridine was added and contents were refluxed for a 8 hrs. The excess of solvent
was removed under reduced pressure and reaction mixture was poured onto
crushed ice. The product was isolated and crystallised from ethanol. Yield
75%(3.6g), m.p. 158oC (C28H23O4N5; Required: C, 68.15; H, 4.67; N, 14.19
; Found: C, 68.31; H, 4.53; N, 14.12%). TLC Solvent system: Acetone : Benzene
(4 : 6).
Similarly, other azalactones were condensed. The physical constants are
recorded in Table No. 3.
[D] Antimicrobial activity of 3-p-Anisyl-5-(2'-phenyl-4'-arylidene-5'-oxo-
imidazolin-1'-yl aminocarbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
















3a C6H5- C27H21O3N5 463 173 0.67 77 15.12 15.07
3b 4-OCH3-C6H4- C28H23O4N5 493 158 0.66 75 14.19 14.12
3c 2-Cl-C6H4- C27H20O3N5Cl 497.5 101 0.74 81 14.08 14.01
3d 4-Cl-C6H4- C27H20O3N5Cl 497.5 148 0.77 80 14.08 13.99
3e 3,4-(OCH3)2-C6H3- C29H25O5N5 523 126 0.89 80 13.38 13.30
3f 2-OH-C6H4- C27H21O4N5 479 185 0.63 77 14.61 14.56
3g 4-OH-C6H4- C27H21O4N5 479 164 0.72 78 14.61 14.53
3h 4-OH-3-OCH3-C6H3- C28H23O5N5 509 104 0.67 71 13.75 13.67
3i CH=CH-C6H5 C29H23O3N5 489 138 0.78 73 14.03 13.96
3j 2-NO2-C6H4- C27H20O5N6 508 140 0.68 82 16.54 16.49
3k 3-NO2-C6H4- C27H20O5N6 508 109 0.62 79 16.54 16.46
3l α-C4H3O- C25H19O4N5 453 124 0.65 83 15.45 15.38
3m 3-OC6H5-C6H4- C32H25O4N5 555 167 0.80 76 12.61 12.55







































B. mega 14 22 16 12 17 21 13 18 14 13 18 12 15 23 22 24
S.aureus 16 11 13 15 13 14 17 12 15 11 14 13 16 22 23 17
P.vulgaris 15 13 12 12 18 11 12 14 13 11 14 14 13 15 18 17
E.coli 18 19 12 15 21 19 13 15 17 16 11 15 19 21 21 23
A.niger 18 16 12 13 15 19 14 22 17 18 15 19 16 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-III
Section - I :  Antimicrobial activity of 3-p-Anisyl-5-(2'-phenyl-4'-arylidene-5'-oxo-imidazolin-1'yl
aminocabonyl) pyrazoles
3b (22) 3g (17) 3b (19) 3a (15) 3f (19)
3f (21) 3e (21) 3e (18) 3h (22)
3f (19) 3l (19)
3m (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






5-pyrazolone is a five membered heterocycle having two nitrogen atoms at
the 1 and 2 positions with carbonyl group at 5-position (I).
SYNTHETIC ASPECT
Different methods are appeared in literature for the preparation of
5-pyrazolones are as under.
1. By the reaction of ethyl acetoacetate with hydrazine hydrate170.
2. By the reaction of ethyl acetoacetate with aryl hydrazine171.
3. By the reaction of ethyl acetoacetate with aroyl hydrazines172.
4. By the reaction of 4,4-dibromo-1,3-substituted-pyrazolin-5-ones with 1-alkyl/
aryl-2,4-dithiobiurets173.
THERAPEUTIC IMPORTANCE
Pyrazolone derivatives exhibit broad spectrum of therapeutic activities. The
























Tokashima Y. et al.185 have synthesised some pyrazolone derivatives which
showed herbicidal activity. Akahane A. et al.186 have synthesised pyrazolone
derivatives which were found to be active against ischemic heart disease such as
angina, diabetes & melancholia. Rajeev Jain et al.187 have prepared pyrazolone
derivatives (II) and reported as potent  antimicrobial agent.
Nakamura K. et al.188 have synthesised some pyrazolone derivatives and
found to be COX-II inhibiting agents useful for the treatment and prevention of
inflammatory conditions, collagen diseases, autoimmune disease, thrombosis,
cancer or neurodegenerative diseases. Yoshikuni et al.189 and Bratusek et al.190



































S. D. Bhardwaj et al.191 have found anticancer and anti-HIV activity.
Nakatsuka M. et al.192 have assessed pyrazolones as immunosuppressants. Banks
B. J. et al.193 have prepared pyrazolone derivatives which were active as
antiparasitic agents.
Some co-worker have prepared pyrazolones and tested them for their
herbicidal and insecticidal194, leukotriene inhibitors195, thromboembotic
disorders196, antiinflammatory and antimicrobial197, coagulation factor198,
anticancer199,200, antiinfective201, antibiotic202, antiinflammatory203,
antimicrobial204, organ transplantation205, therapeutic agent206, antithrombotic
agent207, non-steroidal antiinflammatory drug208, inhibitors of (GSK-3, Aurora-2
and CDK-2)209 activity and also use for treatment of cardiac disorder210.
Thus significant biological properties associated with pyrazolones have
aroused considerable interest to design the compounds in which therapeutically
active pyrazole nucleus is incorporated with a view to obtaining compounds with
better drug potential and to study their pharmacological profile, which have been
described as under.





SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(3'-
METHYL-4'-ARYLHYDRAZONO-5'-OXO-PYRAZOL-1'-YL CARBONYL)
PYRAZOLES
Pyrazolone derivatives are associated with diversified biological properties.
Hence, it was thought of interest that a pyrazolone ring, if coupled to a 3-p-anisyl-
5-hydrazinocarbonyl pyrazole nucleus, the resulting compounds may possess
significant biological potency. Hence, the synthesis of 5-pyrazolones of type (IV)
have been carried out by the condensation of 3-p-anisyl-5-hydrazinocarbonyl
pyrazole with different 2-(substituted phenylhydrazino)-ethyl-2,3-dioxybutyrate,
as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = p-Chlorophenyl = 436, m/z = 437
(m + 1).
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 82. The details












R = ArylType (IV)
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REACTION SCHEME
































IR SPECTRAL STUDY OF (3-p-ANISYL-5-(3'-METHYL-4'-PHENYLHYDRAZONO-5'-OXO-
PYRAZOL-1'-YL CARBONYL) PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2975 2975-2950 549
-CH3 C-H str. (sym.) 2862 2880-2860 "
C-H def. (asym.) 1473 1470-1435 "
C-H def. (sym.) 1371 1385-1370 "
Aromatic C-H str. 3037 3080-3030 550
C=C str. 1527 1520-1480 "
C-H i.p. def. 1093 1125-1090 "
C-H o.o.p. def. 821 835-810 "
Pyrazole N-H str. 3415 3550-3250 549
moiety C=O str. 1668 1680-1630 "
N-H def. 1616 1650-1580 "
C-O-C str. (sym.) 1276 1275-1200 "
C-O-C str. (asym.) 1008 1075-1020 "
Pyrazolone C=O 1703 1710-1660 553




































PMR SPECTRAL STUDY OF 3-p -ANISYL-5- (3 ' -METHYL-4 ' -p -
CHLOROPHENYLHYDRAZONO-5'-OXO-PYRAZOL-1'-YL CARBONYL) PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3+TFA
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.47 - 3H singlet Ar-CH3
2 3.87 - 3H singlet Ar-OCH3
3 7.03 Jab=9 2H doublet Ar-H a,a'
4 7.44 Jdc=9 2H doublet Ar-H d,d'
5 7.48 Jcd=9 2H doublet Ar-H c,c'
6 7.58 - 1H singlet Ar-He
7 7.68 Jba=6 2H doublet Ar-H b,b'






























































































m/z = 436 
m/z = 392 








m/z = 231 
m/z = 201 m/z = 148 
m/z = 120 
m/z = 168 























SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(3'-
METHYL-4'-ARYLHYDRAZONO-5'-OXO-PYRAZOL-1'-YL CARBONYL)
PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 2-(p-Chlorophenylhydrazono)-ethyl-2,3-dioxo-butyrate
p-Chloro aniline (1.27 g. 0.01 M) was dissolved in a mixture of concentrated
HCl (5 ml) and water (5 ml) and cooled to 0-5oC in ice salt bath, cold aqueous
solution of sodium nitrite (0.69 g, 0.01 M) in water (8 ml) was added dropwise
and diazonium salt so formed was filtered into cold mixture of ethylacetoacetate
(1.28 ml, 0.01 M) and sodium acetate (8 g) in ethanol (25 ml). The resulting
solid was filtered and washed with water and crystallised from ethanol. Yield
66%(1.7g), m.p. 128oC, (C12H13N2O3Cl ; Rquired C, 61.97; H, 5.69; N, 11.87
; Found : C, 61.80; H, 5.58; N, 12.01 %). TLC solvent system : Acetone : Benzene
(1.5 : 8.5).
[C] Synthesis of 3-p-Anisyl-5-(3'-methyl-4'-p-chlorophenylhydrazono-
5'-oxo-pyrazol-1'-yl carbonyl) pyrazole
Mixture of 2-(p-Chlorophenylhydrezono) ethyl-2,3-dioxobutyrate (2.68 g,
0.01 M) and 3-p-anisyl-5-hydrazinocarbonyl pyrazole (2.32 g, 0.01 M) in glacial
aceticacid were refluxed for 5 hrs. and allowed it to cool overnight. The resulting
solid was filtered and crystallised from ethanol. Yield 82%(3.5g), m.p. >270oC,
(C21H17O3N6Cl ; Required: C, 57.80; H, 3.90; N, 19.27 ; Found: C, 57.66; H,
3.97; N, 19.23%). TLC solvent system : Acetone : Benzone  (3 : 7).
Similarly, other substituted pyrazolones have been synthesised. The physical
data are recorded in Table No. 4.
[D] Antimicrobial activity of 3-p-Anisyl-5-(3'-methyl-4'-arylhydrazono-
5'-oxo-pyrazol-1'-yl carbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
















4a C6H5- C21H18O3N6 402 211 0.55 79 20.90 20.84
4b 2-OCH3-C6H4- C22H20O4N6 432 209 0.54 73 19.44 19.36
4c 3-OCH3-C6H4- C22H20O4N6 432 171 0.68 80 19.44 19.39
4d 4-OCH3-C6H4- C22H20O4N6 432 198 0.62 88 19.44 19.38
4e 4-F-C6H4- C21H17O3N6F 420 216 0.73  91 20.00 19.94
4f 3-Cl-C6H4- C21H17O3N6Cl 436 180 0.54 77 19.27 19.23
4g 4-Cl-C6H4- C21H17O3N6Cl 436 >270 0.59 82 19.27 19.23
4h 3-Cl-4-F-C6H3- C21H16O3N6FCl 454.5 188 0.60 72 18.48 18.41
4i 3,4-(Cl)2-C6H3- C21H16O3N6Cl2 471 196 0.58 85 17.83 17.76
4j 2-CH3-C6H4- C22H20O3N6 416 220 0.54 81 20.19 20.13
4k 4-CH3-C6H4- C22H20O3N6 416 183 0.65 75 20.19 20.11
4l 2,3-(CH3)2-C6H3- C23H22O3N6 430 174 0.65 88 19.49 19.41
4m 3-NO2-C6H4- C21H17O5N7 447 218 0.62 76 21.92 21.86
4n 4-NO2-C6H4- C21H17O5N7 447 223 0.58 68 21.92 21.85
4o 4-COOH-C6H4- C22H18O5N6 446 228 0.71 85 18.83 18.78







































B. mega 13 18 21 15 22 18 17 16 14 18 12 11 15 17 18 23 22 2
S.aureus 18 12 14 17 11 13 16 12 13 15 16 13 13 14 16 22 23 1
P.vulgaris 13 12 16 11 15 11 11 18 12 13 14 14 13 12 11 15 18 1
E.coli 17 12 14 17 13 15 18 17 18 16 14 13 12 15 17 21 21 2
A.niger 21 17 19 16 15 20 18 22 17 19 23 17 18 14 16 0 0 0









COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-IV
Section - I : Antimicrobial activity of 3-p-Anisyl-5-(3'-methyl-4'-arylhydrazono-5'-oxo-pyrazol-1'yl
carbonyl)pyrazoles
4c (21) 4a (18) 4g (18) 4c (16) 4h (22)
4e (22) 4d (17) 4i (18) 4e (15) 4k (23)
4h (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






The discovery of sulphonamides marked the begining of chemotherapeutic
era by making possible a direct attack on microbial infection211. Sulphonamide
antibacterials continue to be used because they are effective, inexpensive and
free of super infection problems of the broad spectrum antibiotics212.
Sulphonamide have the general  formula of R-SO2-N-R'-R' '  where
R = organic radical, R' and R'' = Hydrogen or organic radical. Depending upon
the nature of R, the sulphonamides are classified as aliphatic, aromatic and
heterocyclic. The aliphatic sulphonamides have not yet become important.
Aromatic and heterocyclic sulphonamides have achieved great commercial
significance. Their application in bacterial chemotherapy is well known.
Considerable interest has been shown in the chemistry of sulphonamides due to
their as antibacterial, anticancer, antimalarial, antifungal, antispasmodic,
anticonvulsant, herbicidal, antiinflammatory and analytical preparation.
SYNTHETIC ASPECT
The different methods for the synthesis of sulphonamides have been
described in literature213-215.
THERAPEUTIC IMPORTANCE
Considerable research has been undertaken to extend the activity and reduce
toxicity of sulpha drugs. Monograms and review216,217 surveying various aspects













Jim A. Turpin and co-workers228 have synthesised some new sulphonamides
which used as anti HIV agents. Morohashi, Hirohisa et al.229 have synthesised
sulphonamides and studied their pharmacological activity and has been found
as anticancer agent. Vazquez M. L. et al.230,231 have synthesised sulphonamide
derivatives as inhibitors of retroviral protease such as human immuno deficiency
virus (HIV). Pamukcu et al.232 have prepared novel sulphonamides (I) which
has been found neoplasticell inhibitors.
Hosuka and co-workers233 have prepared sulphonamides which has been
found ETA-receptor. Bronidge et al.234 synthesised sulphonamide derivatives
which showed CNS disorders agent.  Wu, Chengde and co-workers235











Xiangshu F. et al.236 have found sulphonamide derivatives (II) as new
potential PET breast cancer imaging agents. Owa T. et al.237 have prepared some
novel sulphonamides (III) which has been found antitumor agents.
Kleymann and co-workers238 have synthesised and studied their antiviral
activity. Patrick Y. S. et al .239 have repor ted sulphonamides as novel
anticoagulants. Ilies M. A. et al.240 have prepared sulphonamide derivatives as
carbonic anhydrase inhibitors also inhibit the tumor associated isozyme IX.
CONTRIBUTION FROM OUR LABORATORY
Parikh and co-workers have evaluated sulphonamide derivatives having the
general formula R-SO2-NH-R' where R = phenyl, substituted phenyl, α- and β-
naphthyl and R' = 2,4-disubstituted s-triazine241-243, 4-(1'-aryl-3'-chloro-4'-
methyl-2'-azetidinon-4'-yl) phenyl244, 3-chloro-4-(p-chloro/bromo phenyl)-2-
azet id inone245,  4-(2 ' -ary l -1,3,4-oxadiazo l -5 ' -y l )246,  5-pyr idy l -1,3,4-
oxadiazol247, 1,4-bisaminophthalazine248 and 6-carboxy phenicillanic acid
moieties249 in search of possible antimicrobial agents.












(II) R1 = 4-MeO






















A. R. Parikh et al.250 have demonstrated isoxazoles bearing sulphonamide
linkage as antimicrobial agents. H. H. Parekh et al.251 have synthesised some
new sulphonamides as novel bioactive compounds derived from benzimidazole.
H. H. Parekh et al. have synthesised sulphonamides bearing 8-methyl
quinoline252 and thiazole253 nucleus which were evaluated for their antimicrobial
activity. H. H. Parekh et al.254 have synthesised sulphonamides as antitubercular
agent.
Increasing attention has been focused on sulphonamides due to its
unambiguous efficacy and revealed no. of significant therapeutic activities, this
prompted us to synthesise several sulphonamide derivatives in search of agents
with better drug potential which have been described as under.



















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-
(ARYLSULPHONYLHYDRAZINOCARBONYL) PYRAZOLES
The growing potent l i terature of recent year demonstrates that the
sulphonamide derivatives are used as better therapeutic agents. These finding
prompted us to synthesised 3-p-anisyl-5-(arylsulphonylhydrazinocarbonyl)
pyrazoles of type (V). The synthesis was carried out by condensation of 3-p-anisyl-
5-hydrazinocarbonyl pyrazole with different aryl sulphonyl chlorides, as shown
in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = p-Tolyl = 386, m/z = 387 (m + 1).
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 96. The details


















IR SPECTRAL STUDY OF 3-p-ANISYL-5-(p-TOLYLSULPHONYLHYDRAZINO
CARBONYL) PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2958 2975-2950 549
-CH3 C-H str. (sym.) 2858 2880-2860 "
C-H def. (asym.) 1492 1470-1435 "
C-H def. (sym.) 1353 1385-1370 "
Aromatic C-H str. 3074 3080-3030 550
C=C str. 1593 1585-1570 "
C-H i.p.def. 1095 1125-1090 "
C-H o.o.p. def. 837 835-810 "
Pyrazole N-H str. 3440 3550-3250 549
moiety C=O str. 1666 1680-1630 "
N-H def. 1593 1650-1580 "
(overlapped)
C-O-C str. (sym.) 1234 1275-1200 "
C-O-C str. (asym.) 1018 1075-1020 "
Sulpho- N-H str. 3213 3450-3200 "
namide S=O str. (asym.) 1353 1380-1300 "
S=O str. (sym.) 1161 1180-1110 "







































PMR SPECTRAL STUDY OF 3-p-ANISYL-5-(p-TOLYLSULPHONYL HYDRAZINO
CARBONYL) PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.41 - 3H singlet Ar-CH3
2 3.82 - 3H singlet Ar-OCH3
3 6.80 - 1H singlet Ar-He
4 6.96 Jdc=9 2H doublet Ar-H d,d'
5 7.28 Jab=9 2H doublet Ar-H a,a'
6 7.58 Jcd=9 2H doublet Ar-H c,c'
7 7.66 - 1H singlet -NH
8 7.87 Jba=9 2H doublet Ar-Hb,b'
9 10.96 - 1H singlet -NH














































































































































m/z = 386 
BASE PEAK
m/z = 245 m/z = 362 
m/z = 347 
m/z = 277 
m/z = 232 
m/z = 254 
m/z = 214 
m/z = 155 
m/z = 108 
m/z = 202 
m/z = 308 



























SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-
(ARYLSULPHONYLHYDRAZINOCARBONYL) PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of Arylsulphonyl chloride255
These were prepared by the condensation of different aromatic acids with
chlorosulphonic acid as described by Cremlyn.
[C] Synthesis of 3-p-Anisyl-5-(p-tolylsulphonylhydrazinocarbonyl)
pyrazole
Mixture of p-Tolyl sulphonyl chloride (1.90 g, 0.01 M) and 3-p-anisyl-5-
hydrazinocarbonyl pyrazole (2.32 g, 0.01 M) in pyridine was refluxed for 5 hrs.
The reaction mixture was poured onto crushed ice and product was isolated. It
was crystallised from ethanol. Yield 63%(2.4g), m.p. 194oC, (C18H18O4N4S ;
Required: C, 55.96; H, 4.66; N, 14.51 ; Found: C, 56.11; H, 4.77; N, 14.48 %).
TLC Solvent system : Acetone : Benzene (4.5 : 5.5).
Similarly, other aryl sulphonyl chlorides were condensed. The physical data
are recorded in Table No. 5.
[D] Antimicrobial activity of 3-p-Anisyl-5-(arylsulphonylhydrazino
carbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I. Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 5.
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TABLE NO. 5 : PHYSICAL CONSTANTS OF 3-p-ANISYL-5- (ARYLSULPHONYLHYDRAZINOCARBONYL)
PYRAZOLES
5a 4-NHCOCH3-C6H4- C19H19O5N5S 429 >270 0.71 68 16.32 16.27
5b 2-OCH3-5-NHCOCH3-C6H3- C20H21O6N5S 459 186 0.67 74 15.25 15.19
5c 2-CH3-5-NHCOCH3-C6H3- C20H21O5N5S 443 207 0.54 71 15.80 15.82
5d 2-NHCOCH3-4-Cl-C6H3- C19H18O5N5SCl 463 193 0.65 69 15.10 15.03
5e 3-COOH-4-Cl-C6H3- C18H15O6N4SCl 450 >270 0.60 66 12.43 12.37
5f 3-COOH-6-Cl-C6H3- C18H15O6N4SCl 450 183 0.52 73 12.43 12.35
5g 3-COOH-4-OH-C6H3- C18H16O7N4S 432 >270 0.65 78 12.96 12.91
5h 3-COOH-4-CH3-C6H3- C19H18O6N4S 430 >270 0.50 72 13.02 12.94
5i 3-COOH-4-NO2-C6H3- C18H15O8N5S 461 178 0.58 75 15.18 15.09
5j 3-CH=CH-COOH-C6H4- C20H18N4O6S 442 152 0.72 65 14.07 14.01
5k 4-Cl-C6H4- C17H15O4N4SCl 406 148 0.65 74 13.81 13.74
5l 4-F-C6H4- C17H15O4N4SF 390 217 0.73 77 14.40 14.33
5m 4-CH3-C6H4- C18H18O4N4S 386 194 0.70 63 14.51 14.48
5n 2,4-(Cl)2-C6H3- C17H14O4N4SCl2 441 >270 0.64 67 12.73 12.65




















































B. mega 17 14 15 19 21 18 17 21 16 18 20 14 16 15 23 22 24
S.aureus 22 14 11 15 13 13 15 16 12 11 17 14 13 15 22 23 17
P.vulgaris 13 14 12 11 17 12 11 14 12 14 14 13 13 18 15 18 17
E.coli 17 13 15 18 19 14 11 16 21 20 17 11 13 16 21 21 23
A.niger 19 21 17 16 18 18 20 21 20 18 19 17 18 21 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-V
Section - I : Antimicrobial activity of 3-p-Anisyl-5-(arylsulphonylhydrazinocarbonyl)pyrazoles
5e (21) 5a (22) 5d (18) 5e (17) 5b (21)
5h (21) 5k (17) 5e (19) 5n (18) 5h (21)
5k (20) 5i (21) 5n (21)
5j (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






The aryl substitution products of ammonia are arylamides. Amides, urea,
diamides of carbonic acid are several naturally occurring products. The proteins
and peptides are linear structure of cyclic polyamides. The alkaloids of pepper,
piperine and chavicine are N-substituted amides of unsaturated acids. Amides
derived from polyacetylenic acids have been isolated from certain fungi256.
N-isobutyl amide of certain highly unsaturated aliphatic acid shows insecticidal
activity257 and occur in plants.
SYNTHETIC ASPECT
Several methods are reported in literature258,259 for the preparation of
aryl acetamides.
THERAPEUTIC IMPORTANCE
Amides  and subs t i tu ted amides  are  ac t ive ly  invo lved in  the
pharmacologically useful entities. Some arsano organometallic compounds like













Bartuleweiz et al.270 have assessed arylamides as potential antitumor
antibiotics. Dekeysefi et al.271 have prepared novel arylamide derivatives (I)
and studied their immunomodulator activity.
Sanderson Philip E. J. & Co-workers272 have synthesised arylamides and
studied their biological activity. Moloney, Brian Anthony et al.273 have
synthesised & studied their pharmacological activity which have been found as
an antiulcer agent. Foster James and co-workers274 have synthesised some new
arylamides as potent anticonvulsant. Mulik A. R. and co-workers275 have studied
some arylamides showing antibiotic activity. Bridge Gory et al.276 have prepared
some arylamides and reported their anti-HIV activity. In other study, Laura and
co-workers277 have shown arylamide derivatives analogues as bacterial inhibitors.




















Cudahy et al.279 have synthesised arylamides as antiviral agents. Lau Jespers
et al.280 have reported arylamides as glucokinase (GK) activators. Flohr A. et al.281
have synthesised arylamides as human adenosine receptor.
CONTRIBUTION FROM OUR LABORATORY
Parikh et al.282-284 have synthesised various arylamide derivatives as
antimicrobial agents. Some arylamides having quinoline moieties are also
reported285,286. The general structure and some substituents used are given
below.
H. H. Parekh and co-workers have prepared arylamides having s-triazine
moiety287,288. Some arylamides have been reported to be antifungal and
antibacterial by Parekh et al.289,290
A. R. Parikh et al.291 prepared such derivatives with mild to modest activity.
H. Parekh et al.292 have synthesised new derivatives of arylamide as antibacterial
agent. A. R. Parikh and co-workers293 have synthesised arylamides and
documented as antimicrobial agent. Some novel arylamides prepared by H. H.
Parekh et al.294
In the past years considerable evidence has been accumulated to
demonstrate the pharmacodynamic and chemotherapeutic activities of amide
derivatives. To further assess the potential of such type of compounds, study of
arylamide derivatives have been carried out as described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-p-ANISYL-5-(AROYLHYDRAZINOCARBONYL)
PYRAZOLES













R = Aryl R = Aryl
Arylamides... 99
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-
(AROYLHYDRAZINOCARBONYL) PYRAZOLES
Arylamides represent one of the important classes of compounds having a
broad spectrum of biological activities. With an attempt to getting better
therapeutic agents, the preparation of the arylamides of type (VI) have been
undertaken by the condensation of different acid chlorides with 3-p-anisyl-5-
hydrazinocarbonyl pyrazole, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = o-Tolyl = 350, m/z = 351 (m + 1).
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 109. The details
have been cited in Part (I), Section - I (D).















IR SPECTRAL STUDY OF 3-p-ANISYL-5-(p-METHYLBENZOYLHYDRAZINO
CARBONYL) PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2962 2975-2950 549
-CH3 C-H str. (sym.) 2871 2880-2860 "
C-H def. (asym.) 1454 1470-1435 "
C-H def. (sym.) 1352 1385-1370 "
Aromatic C-H str. 3030 3080-3030 550
C=C str. 1587 1585-1570 "
1527 1520-1480 "
C-H i.p. def. 1137 1125-1090 "
1070 1070-1000 "
C-H o.o.p. def. 825 835-810 "
Pyrazole N-H str. 3448 3550-3250 549
moiety C=O str. 1668 1680-1630 "
N-H def. 1610 1650-1580 "
C-O-C str. (sym.) 1249 1275-1200 "
C-O-C str. (asym.) 1028 1075-1020 "
Amide N-H str. 3294 3450-3200 551,552


































PMR SPECTRAL STUDY OF 3-p-ANISYL-5-(o-METHYLBENZOYLHYDRAZINO
CARBONYL) PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.24 - 3H singlet Ar-CH3
2 3.84 - 3H singlet Ar-OCH3
3 6.92 Jab=9 2H doublet Ar-H a,a'
4 6.93 - 1H singlet Ar-Hc
5 7.14 Jfg=6 Ar-Hf
Jfd=0.9 1H triplet
Jfe=9
6 7.32 Jef=9 1H triplet Ar-He
Jed=6
7 7.53 Jgf=9 1H doublet Ar-Hg
8 7.66 Jde=9 1H doublet Ar-Hd
9 7.78 Jba=9 2H doublet Ar-H b,b'











































































m/z = 350 
BASE PEAK
m/z = 262 
m/z = 246 
m/z = 148 m/z = 106 


















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-
(AROYLHYDRAZINOCARBONYL) PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 3-p-Anisyl-5-(o-methylbenzoylhydrazinocarbonyl)
pyrazole
Mixture of o-Toluic acid (1.36 g, 0.01 M) and thionyl chloride (5 ml) was
refluxed for 6 hrs. Excess of thionyl chloride was removed by distillation. The
acid chloride obtained was refluxed for additional 5 hrs. with 3-p-anisyl-5-
hydrazinocarbonyl pyrazole (2.32 g, 0.01 M) in pyridine, cooled and poured
onto crushed ice. The solid obtained was collected by filteration, the product
washed with sodium bicarbonate and crystallised from ethanol. Yield 68%(2.3g),
m.p. >270oC, (C19H18O3N4 ; Required: C, 65.14; H, 5.14; N, 16.00 ; Found:
C, 65.19; H, 5.03; N, 15.93 %). TLC solvent system: Acetone : Benzene (6 : 4).
Similarly other aromatic acid chlorides were condensed. The physical data
are recorded in Table No. 6.
[C] Antimicrobial activity of 3-p-Anisyl-5-(aroylhydrazinocarbonyl)
pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 6.
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TABLE NO. 6 : PHYSICAL CONSTANTS OF 3-p-5-(AROYLHYDRAZINOCARBONYL) PYRAZOLES
6a C6H5- C18H16O3N4 336 >270 0.65 70 16.66 16.58
6b 4-OCH3-C6H4- C19H18O4N4 366 154 0.73 63 15.30 15.21
6c 2-CH3-C6H4- C19H18O3N4 350 >270 0.67 68 16.00 15.93
6d 2-OH-C6H4- C18H16O4N4 352 187 0.74 66 15.90 15.84
6e 4-OH-C6H4- C18H16O4N4 352 >270 0.81 73 15.90 15.81
6f 2,4-(OH)2-C6H3- C18H16O5N4 368 218 0.55 72 15.21 15.14
6g 3,5-(OH)2-C6H3- C18H16O5N4 368 198 0.56 72 15.21 15.17
6h 3,4-(OCH3)2-C6H3- C20H20O5N4 396 226 0.81 61 14.14 14.06
6i 2-Cl-C6H4- C18H15O3N4Cl 370.5 221 0.66 65 15.11 15.05
6j 4-Cl-C6H4- C18H15O3N4Cl 370.5 198 0.68 70 15.11 15.07
6k 2-F-C6H4- C18H15O3N4F 354 211 0.70 67 15.81 15.75
6l 2-(OCOCH3)-C6H4- C20H18O5N4 394 >270 0.65 71 14.21 14.14
6m 4-NH2-C6H4- C18H17O3N5 351 >270 0.50 71 19.94 19.87
6n 4-NO2-C6H4- C18H15O5N5 381 261 0.58 66 18.37 18.32
6o -CH=CH-C6H5 C20H18O3N4 362 203 0.64 63 15.47 15.41




















































B. mega 20 17 13 15 18 22 12 16 14 15 13 18 13 22 11 23 22
S.aureus 12 15 16 14 11 14 14 13 15 16 17 13 13 11 12 22 23
P.vulgaris 17 13 11 12 12 13 12 11 13 15 12 11 14 13 14 15 18
E.coli 16 12 14 18 17 13 13 15 11 17 15 15 12 13 18 21 21
A.niger 21 19 18 20 17 15 16 22 17 18 15 14 15 18 16 0 0








COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VI
Section - I : Antimicrobial activity of 3-p-Anisyl-5-(aroylhydrazinocarbonyl) pyrazoles
6a (20) 6k (17) 6d (18) 6a (17) 6a (21)
6f (22) 6e (17) 6j (15) 6h (22)
6n (22) 6j (17)
6o (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity







Pyrazoles, which belong to an important group of heterocyclic compounds
has been extensively explored for their applications in the field of medicine,
agriculture and industrial chemistry.
SYNTHETIC ASPECT
Different methods for preparation are available in literature which are as
under.
1. The reaction of hydrazine or its derivatives such as alkyl or aryl hydrazines,
semicarbazide or amino-guanidine with 1,3-dicarbonyl compounds.
2. The reaction of hydrazines with α,β-unsaturated carbonyl compounds.
3. The reaction of aliphetic diazo compounds such as diazomethane or
diazoester with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Pyrazole derivatives exhibits broad spectrum of therapeutic activity several














Barreiro et al.307 have prepared pyrazole derivatives and reported as
ant i in f lammatory and ant idematogenic  agent  M. Gia la et  a l .308have
demonstrated pyrazolone derivatives as antiinflammatory, analgesic and platelet,
antiaggregating agent. El-Emary et al.309 have synthesised 1,3-diphenylpyrazole
derivatives and documented their variety of biological activity (I).
R. Y. Huang and co-worker310 have prepared some 1,2,4-triaryl-4-alkyl-
pyrazoles as estrogen receptor. C. Vittoria and co-worker311 have prepared some
pyrazoles as adenosine receptor antagonist. X. X. Chun et al.312 have prepared
substituted 3-methyl-5-pyrazoles. Carbau Romuald and co-worker313 have
prepared pyrazole derivatives useful as reverse transcriptase inhibitors for the
treatment of HIV infection (II).
Yu Kuolong and co-worker314 have reported antiviral activity of pyrazoles.
Wardakhan et al.315 have demonstrated pyrzole derivatives as fungicidal agent.
Kimura et  a l .316 have prepared pyrazole derivat ives and reported as
antiinflammatory agent. Bebbington et al.317 have suggested pyrazoles as protein
kinase inhibitors. Pevarello Paolo et al.318 have prepared pyrazole derivatives
















as sodium channel blocker. Deminno et al.320 have demonstrated pyrazole
derivatives as treating for cardiovascular disorders. Reddy et al.321 have reported
pyrazoles as COX-2 inhibitor. Anantonarayan et al.322 have prepared pyrazole
derivatives (III) and reported as p38 kinase.
Thus, diverse biological activities have been encountered in compounds
containing pyrazole ring system. To further assess the potential of such type of
compounds, study of pyrazoles have been carried out as described in the
following section.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-p-ANISYL-5-(α-METHYL SUBSTITUTEDBENZAL
HYDRAZINOCARBONYL) PYRAZOLES














SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(α-
METHYL SUBSTITUTEDBENZALHYDRAZINOCARBONYL)
PYRAZOLES
With a view to synthesising the compounds having better therapeutic activity
the hydrazone derivatives of type (VII) have been prepared by the condensation
of 3-p-anisyl-5-hydrazinocarbonyl pyrazole with different aromatic ketones, as
shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
the m/z value indicate the molecular weight, i.e. when R = p-Chlorophenyl =
368, m/z=368.
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 122. The details
have been cited in Part (I), Section - I (D).
















two drop gla. CH3COOH
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IR SPECTRAL STUDY OF 3-p-ANISYL-5- ( α -METHYLBENZALHYDRAZINO
CARBONYL) PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2962 2975-2950 549
-CH3 C-H str. (sym.) 2837 2880-2860 "
C-H def. (asym.) 1442 1470-1435 "
C-H def. (sym.) 1365 1385-1370 "
Aromatic C-H str. 3041 3080-3030 550
C=C str. 1533 1585-1570 "
1508 1520-1480 "
C-H i.p. def. 1116 1125-1090 "
C-H o.o.p. def. 835 835-810 "
Pyrazole N-H str. 3222 3550-3250 549
moiety C=O str. 1654 1680-1630 "
N-H def. 1602 1650-1580 "
C-O-C str. (sym.) 1253 1275-1200 "

































PMR SPECTRAL STUDY OF 3-p-ANISYL-5-(α -METHYL-p-CHLOROBENZAL
HYDRAZINOCARBONYL) PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.33 - 3H singlet -CH3
2 3.79 - 3H singlet Ar-OCH3
3 6.91 Jdc=9 2H doublet Ar-H d,d'
4 7.09 Jba=9 2H doublet Ar-H b,b'
5 7.15 Jcd=9 2H doublet Ar-H c,c'
6 7.80 Jab=9 2H doublet Ar-H a,a'
7 8.34 - 1H singlet Ar-He



























































































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(α-
METHYL SUBSTITUTEDBENZALHYDRAZINOCARBONYL)
PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 3-p-Anisyl-5-(α-methyl-4-chlorobenzalhydrazino
carbonyl) pyrazole
Mixture of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole (2.32 g, 0.01 M) and
p-chloroacetophenone (1.54 g, 0.01 M) in absolute ethanol was refluxed in
waterbath for 8 hrs. in presence of 1 ml glacial aceticacid. The reaction product
was poured onto crushed ice. Crude product was isolated, crystallised from
ethanol. Yield 78%(2.5g), m.p. 189oC, (C19H17O2N4Cl ; Required: C, 61.95;
H, 4.62; N, 15.20 ; Found: C, 62.08; H, 4.71; N, 15.12 %). TLC solvent system:
Acetone : Benzene (1 : 9).
Similarly other hydrazones have been obtained. The physical data are
recorded in Table No. 7.
[C] Antimicrobial activity of 3-p-Anisyl-5-(α-methyl substituted
benzalhydrazinocarbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 7.
119
TABLE NO. 7 : PHYSICAL CONSTANTS OF 3-p-ANISYL-5-(α -METHYL SUBSTITUTEDBENZALHYDRAZINO
CARBONYL) PYRAZOLES
7a C6H5- C19H18O2N4 334 169 0.68 71 16.77 16.68
7b 4-CH3-C6H4- C20H20O2N4 348 203 0.66 68 16.09 16.01
7c 4-OCH3-C6H4- C20H20O3N4 364 185 0.71 67 15.38 15.26
7d 4-Cl-C6H4- C19H17O2N4Cl 368.5 189 0.81 70 15.20 15.12
7e 4-Br-C6H4- C19H17O2N4Br 413 173 0.66 62 13.56 13.47
7f 4-F-C6H3- C19H17O2N4F 352 178 0.50 65 15.91 15.84
7g 2-OH-C6H4- C19H18O3N4 350 211 0.60 73 16.00 15.93
7h 4-OH-C6H4- C19H18O3N4 350 219 0.64 70 16.00 15.95
7i 4-NH2-C6H4- C19H19O2N5 349 183 0.57 74 20.06 20.01
7j α-C4H3O- C17H16O3N4 324 171 0.68 64 17.28 17.17
7k 3-NO2-C6H4- C19H17O4N5 379 185 0.72 63 18.47 18.41
7l 4-NO2-C6H4- C19H17O4N5 379 193 0.78 66 18.47 18.36
7m α-C4H3S- C17H16O2N4S 340 188 0.71 67 16.47 16.41





















































B. mega 19 15 19 17 13 15 14 16 17 20 18 22 16 23 22 24
S.aureus 17 12 14 20 14 15 13 13 16 15 15 14 12 22 23 17
P.vulgaris 13 14 12 14 14 15 13 15 12 14 13 11 13 15 18 17
E.coli 18 15 16 12 17 15 14 13 14 16 13 17 16 21 21 23
A.niger 20 19 18 17 16 15 18 17 15 14 22 18 15 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VII
Section - I : Antimicrobial activity of 3-p-Anisyl-5-(α-methyl substitutedbenzalhydrazinocarbonyl) pyrazoles
7j (20) 7a (17) 7a (18) 7f (15) 7a (20)
7l (22) 7d (20) 7e (17) 7h (15) 7k (22)
7l (17)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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SECTION - II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(3'-
ARYL-4'-FORMYL PYRAZOL-1'-YL CARBONYL) PYRAZOLES
Considerable interest has been shown due to their wide range of biological
activities. Hence it appeared of interest to preparing better therapeutic agents,
i.e. 3-p-anisyl-5-(3'-aryl-4'-formyl pyrazol-1'-yl carbonyl) pyrazoles of type (VIII).
The synthesis was carried out by the reaction of hydrazones with DMF and POCl3
leading to cyclization, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = Phenyl = 372, m/z = 373 (m+1).
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 132. The details
have been cited in Part (I), Section - I (D).



















IR SPECTRAL STUDY OF 3-p-ANISYL-5-[3'-(p-AMINOPHENYL)-4'-FORMYL PYRAZOL-
1'-YL CARBONYL] PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2956 2975-2950 549
-CH3 C-H str. (sym.) 2850 2880-2860 "
C-H def. (asym.) 1452 1470-1435 "
C-H def. (sym.) 1400 1385-1370 "
Aromatic C-H str. 3060 3080-3030 550
C=C str. 1556 1585-1570 "
1508 1520-1480 "
C-H i.p. def. 1147 1125-1090 "
1033 1070-1000 "
C-H o.o.p. def. 835 835-810 "
Pyrazole N-H str. 3226 3550-3250 552
moiety C=O str. (formyl) 1705 1740-1720 "
C=O str. 1660 1680-1630 549
C=N str. 1620 1650-1600 554
C-N str. 1280 1340-1250 "
C-O-C str. (sym.) 1226 1275-1200 549































PMR SPECTRAL STUDY OF 3-p-ANISYL-5-(3'-PHENYL-4'-FORMYL PYRAZOL-1'-YL
CARBONYL) PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.87 - 3H singlet Ar-OCH3
2 7.03 Jab=9 2H doublet Ar-H a,a'
3 7.37 - 1H triplet Ar-He
4 7.47 - 2H triplet Ar-H d,f
5 7.78 - 4H multiplet Ar-Hc,g,i,-NH
6 7.80 Jba=9 2H doublet Ar-H b,b'
7 8.51 - 1H singlet Ar-Hh





















































m/z = 372 
m/z = 120 
m/z = 108 











SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-p-ANISYL-5-(3'-
ARYL-4'-FORMYL PYRAZOL-1'-YL CARBONYL) PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 3-p-Anisyl-5-(α-methyl-4-chlorobenzalhydrazino
carbonyl) pyrazole
See Part - VII, Section - I (B).
[C] Synthesis of 3-p-Anisyl-5-(3'-phenyl-4'-formyl pyrazol-1'-yl carbonyl)
pyrazole
A compound 3-p-Anisyl-5-(α-methyl-4-phenylhydrazinocarbonyl) pyrazole
(3.34 g, 0.01 M) was added in mixture of Vilsmeier-Haack reagent (prepared by
dropwise addition of 4.8 ml POCl3 in ice cooled 20 ml DMF) and refluxed for 5
hrs. The reaction mixture was poured onto crushed ice followed by neutralization
using sodium bicarbonate. Crude product was isolated and crystallised from
ethanol. Yield 77%(2.8g), m.p. 219oC, (C21H16O3N4 ; Required: C, 67.89; H,
4.38; N, 14.97 ; Found: C, 67.74; H, 4.30; N, 15.05 %). TLC solvent system:
Acetone : Benzene (1.5 : 8.5).
Similarly other 4'-formylpyrazoles have been obtained. The physical data
are recorded in Table No. 8.
[D] Antimicrobial activity of 3-p-Anisyl-5-(3'-aryl-4'-formyl pyrazol-1'-yl
carbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 8.
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TABLE NO. 8 : PHYSICAL CONSTANTS OF 3-p-ANISYL-5-(3'-ARYL-4'-FORMYL PYRAZOL-1'-YL CARBONYL)
PYRAZOLES
8a C6H5- C21H16O3N4 372 219 0.81 77 15.05 14.97
8b 4-CH3-C6H4- C22H18O3N4 386 204 0.64 76 14.51 14.43
8c 4-OCH3-C6H4- C22H18O4N4 402 187 0.82 70 13.93 13.87
8d 4-Cl-C6H4- C21H15O3N4Cl 406.5 198 0.72 65 13.78 13.71
8e 4-Br-C6H4- C21H15O3N4Br 451 203 0.78 68 12.42 12.38
8f 4-F-C6H4- C21H15O3N4F 390 218 0.65 69 14.36 14.28
8g 2-OH-C6H4- C21H16O4N4 388 213 0.64 73 14.43 14.33
8h 4-OH-C6H4- C21H16O4N4 388 179 0.64 65 14.43 14.35
8i 4-NH2-C6H4- C21H17O3N5 387 208 0.52 61 18.09 18.01
8j α-C4H3O- C19H14O4N4 362 242 0.55 69 15.47 15.39
8k 3-NO2-C6H4- C21H15O5N5 417 227 0.73 58 16.79 16.69
8l 4-NO2-C6H4- C21H15O5N5 417 >270 0.71 66 16.79 16.73
8m α-C4H3S- C19H14O3N4S 378 195 0.53 63 14.81 14.74



















































B. mega 21 14 22 15 14 17 13 18 16 14 14 12 15 23 22 24
S.aureus 16 14 12 13 15 14 16 13 11 16 12 14 15 22 23 17
P.vulgaris 13 13 12 14 11 14 13 14 18 14 12 15 14 15 18 17
E.coli 17 16 12 13 15 16 14 13 13 15 16 15 15 21 21 23
A.niger 16 18 19 14 21 19 20 16 15 18 17 16 17 0 0 0







GRAPHICAL CHART NO. 8 : ANTIMICROBIAL ACTIVITY OF 3-P-ANISYL-5-(3’-ARYL-4’-FORMYL PYRAZOL-1’-YL
CARBONYL)PYRAZOLES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VII
Section - II : Antimicrobial activity of 3-p-Anisyl-5-(3'-aryl-4'-formyl pyrazol-1'yl carbonyl) pyrazoles
8a (21) 8a (22) 8a (17) 8i (18) 8e (21)
8c (22) 8l (15) 8g (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






Nitriles are reported to possess various therapeutic activities, but due to
their high toxicity, they have low therapeutic importance. The first synthesis of
nitriles has been reported by Wohler and Liebig323 in 1832 and by Pelouze324
in 1834. The term 'Nitrile' was first introduced by Febung325 in 1844. They are
very much useful as intermediates for various products such as acrylonitrile for
plastics, synthetic rubber and fibers, pathalonitrile for dye stuff.
SYNTHETIC ASPECT
Various methods for preparation of nitri les have been reviewed by
D. Mowry.326 Few recent methods are as mentioned below.
1. The pyrolysis of schiff's base327.
2. From halides using NaCN; Al2O3
328.
3. From alkyl halides using KCN, tetra alkyl ammonium salt and water in
trace.329
4. Dehydrating amides using POCl3
330.
MECHANISM























Reaction between CN and aldehyde is type of nucleophilic substitution
reaction. From the above reaction, it can be seen that a nucleophile (CN) attacks
on the carbonyl carbon of aldehyde and yield cyanohydrin, which reacts with
amine to form nitrile derivatives.
THERAPEUTIC IMPORTANCE










Shepherd341 have synthesised nitriles with fused pyridine ring were reported
as ulcer inhibitor. Kobayashi Shigco et al.342 have synthesised new derivatives
of nitrile. M. C. Dougal343 have synthesised nitriles (I) and studied their
pharmacological activities. Lai Hoi Kiong & co-workers344 have reported nitriles
showing fungicidal activity.
Shibata Yasushi and co-workers345 have synthesised nitrile derivatives










new nitr i les and repor ted them as anticonvulsant agent. Yagihara and
co-workers347 have prepared nitr i les which possess antimicrobial and
antiinflammatory activity. Nosyrava et al.348 have prepared novel nitriles which
have been shown to possess muscle relaxant activity. Iwanowicz et al.349 have
synthesised nitriles as inhibitors of IMPDH enzyme. Otaka et al.350 prepared
nitrile derivatives showing pesticidal activity. Iwasa et al.351 synthesised nitriles
and reported as pest control agents.
Adnan A. Bekhit et al.352 have prepared nitriles (II) and reported them as
antimicrobial and antiinflammatory agent.
Alwal Karnail S. et al.353 have synthesised nitri les as inhibitors of
mitochondrial F, Fo, ATPase. Caltherine et al.354 have prepared nitriles having
thromboxane receptor antagonist and thromboxane synthase inhibitors.
CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh, H. H. Parekh and their co-worker have synthesised the nitriles
under the following heading.
* α-Arylamino-α-2-chloro-7-methoxyquinolin-3-yl acetonitriles355 as an
active agents.









Looking to the deversified activities exhibited and in continuation of our
work on the synthesis of biologically active heterocycles, the synthesis and
therapeutic evaluation of nitriles have been described as under.





SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-P-ANISYL-5-
(α -CYANO SUBSTITUTED BENZYLHYDRAZINOCARBONYL)
PYRAZOLES
Looking to the interesting properties of nitriles, with an intension to
synthesising better therapeutic agents, nitrile derivatives of type (IX) have been
synthesised by the action of 3-p-anisyl-5-hydrazinocarbonyl pyrazole with different
aromatic aldehyde by using KCN in the presence of glacial aceticacid at 0-5oC,
as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = o-Chlorophenyl = 380, m/z = 381
(m + 1).
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 146. The details
have been cited in Part (I), Section - I (D).















IR SPECTRAL STUDY OF 3-p -ANISYL-5- ( α -CYANO-p-METHOXYBENZYL
HYDRAZINOCARBONYL) PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2960 2975-2950 549
-CH3 C-H str. (sym.) 2858 2880-2860 "
C-H str. (asym.) 1458 1470-1435 "
C-H def. (sym.) 1367 1385-1370 "
Aromatic C-H str. 3076 3080-3030 550
C=C str. 1508 1520-1480 "
C-H i.p. def. 1112 1125-1090 "
1064 1070-1000 "
C-H o.o.p. def. 825 835-810 "
Pyrazole C=O str. 1668 1680-1630 549
moiety C-O-C str. (sym.) 1242 1275-1200 "
C-O-C str. (asym.) 1024 1075-1020 "
Nitrile N-H str. (sym.) 3328 3350-3200 "

































PMR SPECTRAL STUDY OF 3-p-ANISYL-5- ( α -CYANO-2-CHLOROBENZYL
HYDRAZINOCARBONYL) PYRAZOLE
Internal Standard : TMS
Solvent : CDCl3
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.83 - 3H singlet Ar-OCH3
2 5.35 - 1H singlet -CHc
3 6.77 Jgf=9 1H doublet Ar-Hg
4 6.89 Jfg=6 1H triplet Ar-Hf
Jfe=9
5 6.97 Jab=9 2H doublet Ar-H a,a'
6 7.26 Jdf=3 2H doublet Ar-Hd,e
Jde=6
7 7.29 - 1H singlet Ar-Hh
8 7.49 Jba=6 2H doublet Ar-H b,b'




















































































m/z = 381 
m/z = 273 
m/z = 246 
m/z = 220 m/z = 115 
m/z = 149 

















SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-P-ANISYL-5-(α-
CYANO SUBSTITUTED BENZYLHYDRAZINOCARBONYL) PYRAZOLES
[A] Synthesis of 3-p-Anisyl-5-hydrazinocarbonyl pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 3-p-Anisyl-5-(α -cyano-2-chlorobenzylhydrazino
carbonyl) pyrazole
2-Chloro benzaldehyde (1.40 g, 0.01 M) dissolved in ethanol (10 ml) was
added to potassium cyanide (0.64 g, 0.01 M) dissolved in water (5 ml) followed
by glacial aceticacid (5 ml). The contents were then stirred for five minutes to
from aldehyde cyanohydrin at 0oC. 3-p-anisyl-5-hydrazinocarbonyl pyrazole
(2.32 g, 0.01 M) dissolved in ethanol was added to the reaction mixture, contents
were stirred for 1 hrs. Then kept for 24 hrs. at room temperature and poured
onto crushed ice. The solid product was crystallised from ethanol. Yield
69%(2.6g), m.p. 226oC, (C19H16O2N5Cl ; Required: C, 59.76; H, 4.19; N,
18.35 ; Found: C, 59.81; H, 4.07; N, 18.31 %). TLC solvent system : Acetone :
Benzene (3 : 7).
Similarly, other aromatic aldehydes were condensed. The physical data are
recorded in Table No. 9.
[C] Antimicrobial activity of 3-p-Anisyl-5-(α-cyano substituted
benzylhydrazinocarbonyl) pyrazoles
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 9.
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TABLE NO. 9 : PHYSICAL CONSTANTS OF 3-p-ANISYL-5- (α -CYANOSUBSTITUTED BENZYLHY
DRAZINOCARBONYL) PYRAZOLES
9a C6H5- C19H17O2N5 347 234 0.52 82 20.17 20.09
9b 4-OCH3-C6H4- C20H19O3N5 377 198 0.55 78 18.57 18.52
9c 2-Cl-C6H4- C19H16O2N5Cl 381.5 226 0.65 69 18.35 18.31
9d 4-Cl-C6H4- C19H16O2N5Cl 381.5 262 0.54 74 18.35 18.29
9e 3,4-(OCH3)2-C6H3- C21H21O4N5 407 269 0.81 66 17.20 17.13
9f 2-OH-C6H4- C19H17O3N5 363 281 0.65 79 19.28 19.21
9g 4-OH-C6H4- C19H17O3N5 363 >270 0.80 76 19.28 19.23
9h 4-OH-3-OCH3-C6H3- C20H19O4N5 393 208 0.72 65 17.81 17.73
9i -CH=CH-C6H5 C21H19O2N5 373 253 0.68 61 18.77 18.70
9j 2-NO2-C6H4- C19H16O4N6 392 >270 0.65 73 21.43 21.39
9k 3-NO2-C6H4- C19H16O4N6 392 257 0.63 68 21.43 21.36
9l α-C4H3O- C17H15O3N5 337 223 0.70 65 20.77 20.72
9m 3-OC6H5-C6H4- C25H21O3N5 439 >270 0.58 71 15.95 15.90



















































B. mega 19 12 15 14 16 21 14 16 18 19 17 15 17 23 22 24
S.aureus 16 12 15 14 22 16 14 16 17 15 13 15 14 22 23 17
P.vulgaris 14 13 11 14 13 15 13 14 12 11 14 12 17 15 18 17
E.coli 16 18 12 21 15 17 16 14 19 17 13 11 18 21 21 23
A.niger 18 17 15 16 21 17 16 23 16 17 19 14 16 0 0 0







GRAPHICAL CHART NO. 9 : ANTIMICROBIAL ACTIVITY OF  3-P-ANISYL-5-(α-CYANO  SUBSTITUTED  BENZYLHYDRAZINO
CARBONYL)PYRAZOLES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VIII
Section - I : Antimicrobial activity of 3-p-Anisyl-5-(α-cyano substitutedbenzylhydrazinocarbonyl) pyrazoles
9f (21) 9e (22) 9b (18) 9f (15) 9e (21)
9i (17) 9d (21) 9m (17) 9h (23)
9i (19)
9m (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






The furan ring system is found in many naturally occurring compounds,
either as a fully unsaturated structure or in a reduced or partly reduced form.
Furan which occur in nature in a reduced or otherwise modified form include
pentose sugars which as ribose and deoxyribose, which are components of nucleic
acids and several types of unsaturated γ-lactone such as ascorbic acid.
Introduction of a different side chain completely alters the pharmacological
profile leading to a new class of muscle relaxants. i.e. clodanolene (I).
The presence of furan ring is also compatible with cimetidine which has
antiulcer activity a biaryl propionic acid derivative containing a furan ring as
























Different methods for the preparation fo furan derivatives are as under:
1. Diazof i sed so lu t ion o f  p-aminobenzo ic  ac id  wi th  fur fura l  g ives
4-[2'-(5'-formyl) furyl] benzoic acid.357
2. By Michael reaction.358
3. Synthesis of substituted furans using 1,4-Dioxan.359
THERAPEUTIC  IMPORTANCE
Literature survey revealed that various furans have resulted in many potential
drugs and are known to exhibit a broad spectrum of biological activities such as:
1. Insecticidal360








Preparation of furan derivatives for inhibition of pneumocystis carinil
pneumonia, giardia lamblia and cryptospordium parvum have been undertaken
by Boykin David M. et al.369 B. Shivarama Hulla et al.370 have prepared furan
















Black Cameron et al.371 have evaluated furan derivatives as COX-2
inhibitors. B. Shivarama Hulla et al.372 have prepared furan derivatives (IV)
which possess antiinflammatory & antibacterial activity.
Francesconi Iris et al.373 have assessed 2,4-diphenyl furan diamidines as
novel antipneumocystis carini pnemonia agents. Preparation of aryl furan
derivatives as PDE IV inhibitors have been undertaken by Helene Perrier et al.374
Antitumor activity of furopyrimidines have been observed by Vivian Cody
et al.375  Oomura Osama et al.376 have prepared furan derivatives (V) which
shows antiulcer activity.
Petpiboon et al.377 have synthesised furan derivatives as inhibitor of
cyclogenase-2 and -1. M. M. Rao and D. G. Kingston378 have prepared furan
derivat ives which possess cytotoxic act ivi ty.  Preparat ion of some 3,4-
diacyloxyfurans as prodrug for antioxidants have been undertaken by Sasaki
Tsutomu et al.379 Furan derivatives has been studied by Collot Valerie et al.380
which shows cardiovascular activity. Cheng et al.381 have synthesised
furopyridines and related compounds as P-38 MAP kinase inhibitors. Wang,
Zhaoyin et al.382 have prepared furan derivatives as selective cyclooxygenase-
2-inhibitors. Y. Cheng Chen383 have prepared furan derivatives which are useful





















Anti-HIV active furan derivatives have been claimed by Battistino L. and et al.384
Nguyen et al.385 have synthesised furan derivatives which possess antibacterial
and antifungal activity. Dijcks et al.386 have demonstrated furan derivatives which
are useful in psychotherapeutics. Srinivas C. et al.387 have prepared furan
derivatives as potential antifeedant. Banavara L. Mylari et al.388 synthesised furan
derivatives which possess a highly selective, non-hydantoin, reductase with potent
oral activity in diabetic rat models. Antitumor activity & preliminary toxicity of
furan derivatives have been claimed by Vuquiang Wang et al.389 Ravindra V. et al.390
have demonstrated furan derivatives which are useful in antimicrobial agent.
Miller Christopher P. et al.391 have synthesised furan derivatives as estogentic
agents. Tulshian et al.392 synthesised furan derivatives as adenosine A2A receptor
antagonist. Preparation of furan derivatives as protein tyrosine phosphatase 1B
inhibitors have been undertaken by Mjalli, Adnan M. M. et al.393
Literature reveals that the compounds bearing furyl nucleus in general
possess potential drug activity. Looking to the diversified biological activities, it
appeared of interest to synthesised some isoxazoles, pyrimidines and barbituric
acid derivative bearing 5-p-acetophenyl furan-2-carboxylic acid nucleus in order
to achieving compounds having better therapeutic activity. This study is described
in the following parts:
[B] STUDIES ON FURANS
PART - I : STUDIES ON CHALCONES
PART - II : STUDIES ON ISOXAZOLES
PART - III : STUDIES ON THIOPYRIMIDINES






Benzylidene acetophenones constitute a class of naturally occurring
pigments, which are often referred to as ''Chalcones''. The term was first coined
by Kostanecki394, who did  pioneering work in the synthesis of naturally colouring
compounds.
The chemistry of chalcones has generated intensive scientific study
throughout the world, specially interesting are their biological and industrial
applications Chalcones are characterised by their possession of a structure in
which two aromatic ring A and B are linked by an aliphatic three carbon
chain (I).
The alternative names given to chalcones are phenyl styryl ketones,
benzalacetophenone, β-phenyl acrylphenone, γ-oxo-α,γ-diphenyl, α-propylene
and α-phenyl-β-benzoethylene.
SYNTHETIC ASPECT
A considerable variety of methods are available for the preparation of
chalcones. The most convenient method is the one that involves the Claisen
Schmidtt condensation395-397.
Various condensing agents used are alkali of different strength398,399,
hydrogenchloride400,401, phosphorousoxychloride402, piperidine403,
anhydrous aluminiumchloride404, borontrifluoride405, aqueous solution of






Chalcone formation proceeds through aldol type of condensation and the
process is catalysed by the presence of alkali409. Following are the step of the
reaction mechanism.
The intermediate aldol type of products formed redily undergoes dehydration
even under mild condition, particularly when R and R' are aryl groups.
THERAPEUTIC IMPORTANCE
Chalcones are potential biocides, some naturally occuring antibiotics and
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Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives has been reported by Modi et al.424 and Kammei et al.425 have
synthesised chalcone derivatives having antitumor activity. De Vincenzo et al.426
and Han et al.427 have reported chalcone derivatives for their antiinflammatory
activity. Preparation of chalcone derivatives (II) for the treatment of inflammation
and cardiovascular disease as reported by Worsencroft et al.428
E. Bombardelli et al.429 have demonstrated that chalcones possess a
valuable antiproliferation activity both on sensitive cancereous cell and on cell
which are resistant to common chemotherapeutic drugs. Anticancer activity of
chalcones have been observed by Toru and Yoshihito430. J. R. Dimmock et al.431
have prepared chalcones and observed their antimicrobial activity.
Anti-tuberculosis agents of chalcone derivatives is documented by Lin
et al.432 Archana et al.433 have reported anticonvulsant activity of chalcone
derivatives. Kumar et al.434 have synthesised novel boronic-chalcone derivatives
as antitumor agents. Jiu-Hong et al.435 prepared some chalcones and observed
their potent anti-HIV activity. Kim et al.436 have reported chalcones as matrix
metaloproteianse inhibitors. Some of the chalcones have been patented for their
use for therapeutic agent437, antiproliferative agent438, cytotoxic agent439,











R2-R6, R2a-R6a = H, halo, nitro, alkyl
Chalcones... 153
Chalcone bearing a very good synthon, variety of novel heterocycles with
good pharmacological profile can be designed. These valid observation led us
to explore chalcone chemistry by synthesising several derivatives like isoxazoles,
thiopyrimidines and barbitones bearing different heterocyclic ring systems for
medicinal value, in order to achieving better therapeutic agents, this study
described as under.





SYNTHESIS AND THERAPEUTIC EVALUATION OF 1- (p-2 ' -
CARBOXYFURAN-5'-YL PHENYL)-3-ARYL-2-PROPENE-1-ONES
As a part of our drug discovery program, considerable evidence has been
accumulated to demonstrate the efficiency of chalcones in inducing variety of
therapeutic activities. Our interest in further exploration in such a class of
compounds as antibacterial agent led us to synthesise, a series of chalcones of
type (X) by the condensation of 5-p-acetophenyl furan-2-carboxylic acid with
different aromatic aldehydes in presence of NaOH, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = p-Anisyl = 348, m/z = 349 (m + 1).
The products have been screened for their in vitro biological activity like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37 Rv
at a concentration of 6.25 µg using Rifampin as a standard drug, antibacterial
activities towards Gram positive and Gram negative bacterial strains and antifungal
activity towards Aspergillus niger at  a  concentration of 40 µg. The biological
activities of the synthesised compounds were compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known antibiotics recorded on page 166. The details have been cited in
Part (I), Section - I (D).
OHOOC O
R
R = ArylType (X)
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REACTION SCHEME

























IR SPECTRAL STUDY OF 1-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-3-p-ANISYL-2-PRO-
PENE-1-ONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2954 2975-2950 549
-CH3 C-H str. (sym.) 2873 2880-2860 "
C-H def. (asym.) 1454 1470-1435 "
C-H def. (sym.) 1363 1390-1370 "
Aromatic C-H str. 3058 3080-3030 550
C=C str. 1515 1520-1480 "
C-H i.p. def. 1020 1070-1000 "
C-H o.o.p. def. 829 835-810 "
Furyl C=O str. 1726 1720-1655 549
moiety C-O-C str. (sym.) 1207 1275-1200 "
C-O-C str. (asym.) 1020 1075-1020 "
(overlapped)
Chalcone CH=CH 3058 3050-3000 551
(overlapped)
C=O str. 1645 1685-1645 549


























PMR SPECTRAL STUDY OF 1-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-3-p-ANISYL-2-
PROPENE-1-ONE
Internal Standard : TMS
Solvent : CDCl3+DMSOd6
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.85 - 3H singlet Ar-OCH3
2 6.95 Jdc=6 2H doublet Ar-H d,d'
- 1H singlet Ar-He
3 7.26 Jfe=3 1H doublet Ar-Hf
4 7.48 Jgh=15 1H doublet =CHg
5 7.65 Jba=9 2H doublet Ar-H b,b'
6 7.77 Jhg=15 1H doublet =CHh
7 7.91 Jab=9 2H doublet Ar-H a,a'
8 8.08 Jcd=9 2H doublet Ar-H c,c'





















































































m/z = 348 
BASE PEAK
m/z = 318 
m/z = 274 








































SYNTHESIS AND THERAPEUTIC EVALUATION OF 1- (p-2 ' -
CARBOXYFURAN-5'-YL PHENYL)-3-ARYL-2-PROPENE-1-ONES
[A] Synthesis of 5-p-Acetophenylfuran-2-carboxylic acid
Mixture of p-Aminoacetophenone (13.5 g, 0.1 M), dil. HCl (15%, 60 ml)
and water (90 ml) was heated to get a clear solution. The solution was cooled to
0oC and diazotised with NaNO2 solution (30%, 24 ml). The diazonium salt
solution was filtered and to the filtrate, water (50 ml) and furoic acid (11.2 g,
0.1 M) and aqueous cupric chloride (2.5 g, in 10 ml of water) were added with
stirring. The stirring was continued for 4 hrs. and kept overnight. The separated
solid was collected by filtration and washed with cold ethanol. The crude
compound was recrystallised from ethanol. Yield 87%(20g), m.p. 192oC,
(C13H10O4 ; Required: C, 67.83; H, 4.35 ; Found: C, 67.98; H, 4.21%). TLC
solvent system: Acetone: Benzene (3 : 7).
[B] Synthesis of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-p-anisyl-2-
propene-1-one
To a well stirred solution of 5-p-Acetophenylfuran-2-carboxylic acid (2.30 g,
0.01 M) and p-methoxybenzaldehyde (1.36 g, 0.01 M) in ethanol (25 ml), 40%
NaOH added till the solution was basic. The reaction mixture was stirred for 24
hrs. The contents were poured into ice, acidified, filtered and crystallised from
glacial aceticacid. Yield 88%(3.0g), m.p. 244oC, (C21H16O5 ; Required:
C, 72.41; H, 4.60 ; Found: C, 72.58; H, 4.67 %). TLC solvent system: Acetone:
Benzene (5 : 5).
Similarly, other aromatic aldehydes were condensed. The physical data are
recorded in Table No. 10.
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[C] Antimicrobial activity of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-aryl-
2-propene-1-ones
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 10.
The antitubercular activity of the compounds of type (X) was carried out by
TAACF, the Southern Research Institute, U.S.A. as described in Part - I, Section
-I (D), and the percentage of inhibition data of the compounds are recorded in
Table No. 10a.
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TABLE NO. 10 : PHYSICAL CONSTANTS OF 1-(p-2'-CARBOXYFURAN-5' YL PHENYL)-3-ARYL-2-PROPENE-1-
ONES
10a C6H5- C20H14O4 318 207 0.75 84 - -
10b 4-OCH3-C6H4- C21H16O5 348 244 0.73 88 - -
10c 2-Cl-C6H4- C20H13O4Cl 352.5 187 0.81 89 - -
10d 4-Cl-C6H4- C20H13O4Cl 352.5 >270 0.72 78 - -
10e 3,4-(OCH3)2-C6H3- C22H18O6 378 204 0.58 87 - -
10f 2-OH-C6H4- C20H14O5 334 201 0.62 76 - -
10g 4-OH-C6H4- C20H14O5 334 227 0.52 71 - -
10h 3-OCH3-4-OH-C6H3- C21H16O6 364 198 0.38 76 - -
10i CH=CH-C6H5 C22H16O4 344 179 0.71 92 - -
10j 2-NO2-C6H4- C20H13O6N 363 241 0.67 75 3.85 3.78
10k 3-NO2-C6H4- C20H13O6N 363 233 0.72 85 3.85 3.80
10l α-C4H3O- C18H12O5 308 216 0.57 86 - -
10m 3-OC6H5-C6H4- C26H18O5 410 156 0.56 89 - -
10n 4-SCH3-C6H4- C21H16O4S 364 193 0.64 83 - -
10o 2,7-(Cl)2-C9H4N- C23H13O4NCl2 438 217 0.69 81 3.19 3.13



















































B. mega 22 14 12 19 16 15 18 21 17 19 16 17 15 22 23 22 2
S.aureus 15 16 14 13 13 16 16 17 12 15 14 17 14 14 22 23 1
P.vulgaris 12 17 14 13 12 14 13 14 14 18 12 12 13 11 15 18 1
E.coli 16 14 12 15 11 18 19 17 14 15 14 15 16 17 21 21 2
A.niger 19 23 21 14 22 18 16 20 22 21 19 20 18 17 0 0







GRAPHICAL CHART NO. 10 : ANTIMICROBIAL ACTIVITY OF 1-( P-2’-CARBOXYFURAN-5’-YL PHENYL)-3-ARYL-2-PROPENE-
1-ONES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-I
Section - I : Antimicrobial activity of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-aryl-2-propene-1-ones
10a (22) 10h (17) 10f (18) 10b (17) 10b (23)
10h (21) 10l (17) 10g (19) 10j (18) 10e (22)
10n (22) 10i (22)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TABLE NO. 10a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
162015 AB-30 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 65
162019 AB-34 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 58  ''
162018 AB-33 α-C4H3O- Sau.uni Alamar H37Rv >6.25 39  ''
162014 AB-29 C6H5- Sau.uni Alamar H37Rv >6.25 38  ''
162024 AB-39 2-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 21  ''
162026 AB-41 2,7-(Cl)2-C9H4N- Sau.uni Alamar H37Rv >6.25 18  ''
162020 AB-35 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 11  ''
162025 AB-40 3-OC6H5-C6H4- Sau.uni Alamar H37Rv >6.25 2  ''
162016 AB-31 2-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162017 AB-32 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162021 AB-36 4-OH-3-OCH3-C6H3- Sau.uni Alamar H37Rv >6.25 0  ''
162022 AB-37 -CH=CH-C6H5 Sau.uni Alamar H37Rv >6.25 0  ''
162023 AB-38 3-NO2-C6H4- Sau. uni. Alamar H37Rv >6.25 0 "
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.025mg/ml









In 1888, Claisen first suggested an isoxazole (I), a product from the reaction
of 1,3-diketone with hydroxylamine442. Subsequently a solid foundation for the
chemistry of isoxazoles was laid down by Claisen and his students.
It was found to possess typical properties of an aromatic system but under
certain reaction conditions, particularly in reducing or basic media, it becomes
highly labile. Quelico in 1964, made the next important contribution to the
chemistry of isoxazole, he began to study the formation of isoxazoles from nitrile
N-oxides and unsaturated compounds443.
SYNTHETIC ASPECT
It can be prepared by the following different methods:
1. Subst i tuted isoxazoles  were prepared f rom the react ion between
hydroxy lamine hydroch lor ide  and cha lcones444 or  cha lcone
dibromides445.
2. J. F. Hansen and S. A. Strong446 isolated isoxazoles from α,β-unsaturated
ketones and N-bromosuccinimide.
3. Franshawe and Crawley447 prepared isoxazoles  f rom diketones,
hydroxylamine hydrochloride and KOH in methanol.
4. S. Auricchia448 has synthesised 3-anilino-5-phenyl-isoxazoles by the
reaction of hydrazine and hydroxylamine or acetylenic thiomides.





















Sezer Ozkan et al.470 have prepared 3-(1-phenyl-1,2,3-triazol-4-yl)-





























D. A. Jacob et al .471 have prepared isoxazoles and documented
antiinflammatory activity. Some, isoxazoles are found to possess herbicidal472,
antimicrobial agents473 and inhibitor of p38 MAP kinase activities.474 R. Ulrich
et al.475 have synthesised isoxazoles and reported their adrenergic antagonist
activity. Chuanmin et al.476 have prepared isoxazoles as herbicidal agent.
Wu Chengde et al.477 have prepared isoxazole derivatives (IV) as endothelin
activity modulators.
Anticonvulsant activity of isoxazoles has been reported by Archana478.
Some isoxazoles are found to possess antibacterial479, antimicrobial480 activity.
CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh et al.481 have prepared isoxazoles as an antimicrobial agents.
H. H. Parekh et al.482 have prepared isoxazoles and reported as potential
antitubercular agents. A. R. Parikh et al.483 have synthesised some new
isoxazoles. 3-(3'-bromo-4-acetamidophenyl)-5-aryl-isoxazoles have prepared by
A. R. Parikh and co-workers484. A. R. Parikh et al.485 have prepared some
isoxazoles and reported their antimicrobial activity.  A. R. Parikh et al.486 have

















The development of efficient and selective synthesis of isoxazoles has
attracted increasing attention over the last several years, because they often bring
about unique physiological properties. These findings encouraged us to search
isoxazoles bearing furan moiety.





SYNTHESIS AND THERAPEUTIC EVALUATION OF 3- (p-2 ' -
CARBOXYFURAN-5'-YL PHENYL)-5-ARYL-ISOXAZOLES
Looking to the wide range of therapeutic activities of isoxazole derivatives,
it was thought worthwhile to prepare 3-(p-2'-carboxyfuran-5'-yl phenyl)-5-aryl
isoxazoles (XI) from chalcones of type (X) in presence of hydroxylamine
hydrochloride, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = 3,4 Dimethoxyphenyl = 391,
m/z = 391.
The products have been screened for their in vitro biological activity like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37 Rv
at a concentration of 6.25 µg using Rifampin as a standard drug, antibacterial
activities towards Gram positive and Gram negative bacterial strains and antifungal
activity towards Aspergillus niger at  a  concentration of 40 µg. The biological
activities of the synthesised compounds were compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known antibiotics recorded on page 181. The details have been cited in
Part (I), Section - I (D).










IR SPECTRAL STUDY OF 3-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-5-p-ANISYL-
ISOXAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2952 2975-2950 549
-CH3 C-H str. (sym.) 2852 2880-2860 "
C-H def. (asym.) 1477 1470-1435 "
C-H def. (sym.) 1342 1390-1370 "
Aromatic C-H str. 3076 3080-3030 550
C=C str. 1523 1520-1480 "
C-H i.p. def. 1074 1070-1000 "
C-H o.o.p. def. 827 835-810 "
Furyl C=O str. 1689 1720-1655 549
moiety C-O-C str. (sym.) 1209 1275-1200 "
C-O-C str. (asym.) 1031 1075-1020 "
Isoxazole C=N str. 1600 1650-1555 "





























PMR SPECTRAL STUDY OF 3-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-5-p-ANISYL-
ISOXAZOLE
Internal Standard : TMS
Solvent : CDCl3+TFA
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.87 - 3H singlet Ar-OCH3
2 6.90 Je=3 1H doublet Ar-He
3 6.93 Jba=3 2H doublet Ar-H b,b'
4 7.27 Jf=3 1H doublet Ar-Hf
5 7.55 - 1H singlet Ar-Hg
6 7.81 Jab=3 2H doublet Ar-H a,a'
7 7.90 Jdc=6 2H doublet Ar-H d,d'
8 7.94 Jcd=6 2H doublet Ar-H c,c'




















































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3- (p-2 ' -
CARBOXYFURAN-5'-YL PHENYL)-5-ARYL-ISOXAZOLES
[A] Synthesis of 5-p-Acetophenylfuran-2-carboxylic acid
See part (I), Section - I (A).
[B] Synthesis of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-p-anisyl-2-
propene-1-one
See part (I), Section - I (B).
[C] Synthesis of 3-(p-2'-Carboxyfuran-5'-yl phenyl)-5-p-anisyl-isoxazole
Mixture of Hydroxylamine hydrochloride (0.79 g, 0.01 M) in ethanol and
anhydrous sodium acetate (0.82g, 0.01 M) dissolved in minimum amount of hot
acetic acid was added a solution of 1-(p-2'-carboxyfuran-5'-yl phenyl)-3-p-anisyl-
2-propene-1-one (3.48 g, 0.01 M) in ethanol (15 ml). The contents were refluxed
on waterbath for 8 hrs. The reaction product was poured into ice and crystallised
from ethanol. Yield 77%(2.7g), m.p. 193oC, (C21H15O5N ; Required: C, 69.81;
H, 4.16; N, 3.89 ; Found : C, 69.72; H, 4.29; N, 3.82%). TLC solvent system:
Acetone : Benzene (4.5 : 5.5).
Similarly other substituted isoxazoles have been prepared. The physical data
are recorded in Table No. 11.
[D] Antimicrobial activity of 3-(p-2'-Carboxy furan-5'-yl phenyl)-5-aryl-
isoxazoles
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 11.
The antitubercular activity of the compounds of type (XI) was carried out by
TAACF, the Southern Research Institute, U.S.A. as described in Part - I, Section - I (D),
and the percentage of inhibition data of the compounds are recorded in Table
No. 11a.
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TABLE NO. 11 : PHYSICAL CONSTANTS OF 3-(p-2'-CARBOXYFURAN-5' YL PHENYL)-5-ARYL-ISOXAZOLES
11a C6H5- C20H13O4N 331 177 0.78 79 4.22 4.17
11b 4-OCH3-C6H4- C21H15O5N 361 193 0.72 77 3.89 3.82
11c 2-Cl-C6H4- C20H12O4NCl 365.5 235 0.48 70 3.83 3.76
11d 4-Cl-C6H4- C20H12O4NCl 365.5 235 0.70 78 3.83 3.78
11e 3,4-(OCH3)2-C6H3- C22H17O6N 391 185 0.82 66 3.60 3.53
11f 2-OH-C6H4- C20H13O5N 347 132 0.51 78 4.03 3.95
11g 4-OH-C6H4- C20H13O5N 347 126 0.78 75 4.03 3.98
11h 3-OCH3-4-OH-C6H3- C21H15O6N 377 138 0.72 69 3.71 3.66
11i -CH=CH-C6H5 C22H15O4N 357 167 0.55 82 3.92 3.85
11j 2-NO2-C6H4- C20H12O6N2 376 158 0.81 79 7.45 7.38
11k 3-NO2-C6H4- C20H12O6N2 376 242 0.67 73 7.45 7.36
11l α-C4H3O- C18H11O5N 321 238 0.68 69 4.36 4.28
11m 3-OC6H5-C6H4- C26H17O5N 423 122 0.69 64 3.31 3.26
11n 4-SCH3-C6H4- C21H15O4SN 377 154 0.52 61 3.71 3.66
11o 2,7-(Cl)2-C9H4N- C23H12O4N2Cl2 451 207 0.56 81 6.21 6.15



















































B. mega 18 14 16 17 12 21 13 15 14 17 16 15 16 17 20 23 22
S.aureus 15 22 14 16 16 15 13 14 16 15 17 13 14 14 12 22 23
P.vulgaris 14 14 17 13 12 18 11 14 13 13 14 13 14 12 11 15 18
E.coli 16 12 15 16 14 15 13 16 17 14 13 18 16 15 17 21 21
A.niger 19 18 17 16 12 14 13 19 18 17 16 15 19 21 15 0 0







GRAPHICAL CHART NO. 11 : ANTIMICROBIAL ACTIVITY OF 3-( P-2’-CARBOXYFURAN-5’-YL PHENYL)-5-ARYL-
ISOXAZOLES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-II
Section - I : Antimicrobial activity of 3-(p-2'-Carboxyfuran-5'-yl phenyl)-5-aryl-isoxazoles
11f (21) 11b (22) 11i (17) 11c (17) 11n (21)
11o (20) 11k (17) 11l (18) 11f (18)
11o (17)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TABLE NO. 11a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
162027 AB-42 C6H5- Sau.uni Alamar H37Rv >6.25 64
162030 AB-45 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 64  ''
162033 AB-48 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 56  ''
162031 AB-46 α-C4H3O- Sau.uni Alamar H37Rv >6.25 51  ''
162034 AB-49 4-OH-3-OCH3-C6H3- Sau.uni Alamar H37Rv >6.25 41  ''
162028 AB-43 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 33  ''
162035 AB-50 -CH=CH-C6H5 Sau.uni Alamar H37Rv >6.25 33  ''
162039 AB-54 2,7-(Cl)2-C9H4N- Sau.uni Alamar H37Rv >6.25 20  ''
162032 AB-47 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 14  ''
162036 AB-51 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 7  ''
162038 AB-53 3-OC6H5-C6H4- Sau.uni Alamar H37Rv >6.25 3  ''
162029 AB-44 2-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162037 AB-52 2-NO2-C6H4- Sau. uni. Alamar H37Rv >6.25 0 "
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.025mg/ml










Thiopyrimidine derivatives are an important class of pharmaceutically active
compounds and their chemistry was extensively studied and continues to attract
the attention of synthetic chemists. The thiopyrimidine derivatives and many
heterocyclic compounds containing thiopyrimidine moiety are known to have
major pharmacological activities. In addition to various pharmacological
properties, thiopyrimidines are useful for the synthesis of tri and tetra-cyclic
heterocyclic compounds.
SYNTHETIC ASPECT
Different method487-489 are available for the preparation of marcapto
pyrimidine derivatives. The well known methods are,
1. The reaction of chalcones with thiourea in alkaline medium afforded
corresponding mercapto pyrimidine derivatives490.
2. Liu - Fang Ming et al.491 have synthesised mercapto pyrimidine by the
reaction of 1,3-di-ketones and thiourea.
3. Mercapto pyrimidines can also be obtained by the condensation of
β-dinitriles with thiourea and guanidines492.
THERAPEUTIC IMPORTANCE
From the literature survey it was revealed that mercapto pyrimidines are
better therapeutic agents. The important biological activities shown as under.























V. Peesapati and co-worker506 have prepared thiopyrimidines documented
as potent antimicorbial agent. Mahran et al.507 have synthesised heterocyclic
system containing thiopyrimidine nucleus as potential antimicrobial and
antitumor agent. M. Saneyoshi and co-worker508 have synthesised thiopyrimidine
nucleosides as anticancer and antiviral agent. K. Daniel et al.509 have synthesised
some novel thiopyrimidines possessing anti HIV activity.














S. A. Swelan511 have reported furopyrimidines which possess antitumor
activity. H. Allimony512 have prepared thiopyrimidines and reported as potent
antimicrobial agent. R. Robert et al.513 have prepared thiopyrimidines and studied
their herbicidal activity.
Abou El-Fottoh et al.514 have prepared thiopyrimidine derivatives (IV)
which showed anticancer activity.
Sondhi sham and co-workers515 have prepared thiopyrimidine derivatives
which found to possess antiinflammatory, analgesic and antiamoebic activity.
N. M. Saleh and co-workers516 have prepared pyrimidines and reported their
pharmacological activity. Hu Chun, Ding and co-workers517 have evaluated
thiopyrimidines as Ca-antagonist agents.
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh et al.518,519 have synthesised pyrimidine derivatives and
reported their antitubercular activity. A. R. Parikh et al.520,521 also synthesised












X = Cl, Br, I,
3,4-(OCH3)2
Thiopyrimidines... 185
A. R. Parikh, H. H. Parekh and their co-worker have synthesised
thiopyrimidines under the following heading.
* Synthesis of thiopyrimidines522 as a biologically agents.
* Synthesis and biological evaluation of thiopyrimidine523 derivatives.
Thus significant biological properties associated with thiopyrimidines have
aroused considerable interest to design the compounds in which therapeutically
active furan nucleus is incorporated and to study their pharmacological profile,
which have been described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF




SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-THIO-4-ARYL-
6-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-1,2,3,4-TETRAHYDRO
PYRIMIDINES
Considerable attention has been focussed on the development and synthesis
of 1,3-thiazine derivatives of type (XII) for obtaining biologically potent molecules
which have been prepared by the cyclocondensation of chalcones of type (X)
with thiourea in alc. KOH solution, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = p-Anisyl = 406, m/z = 407 (m + 1).
The products have been screened for their in vitro biological activity like
antibacterial activities towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at  a  concentration of 40 µg.
The biological activities of the synthesised compounds were compared with
standard drugs. Some compounds have been found to have good and equivalent
activity as compared to the known antibiotics recorded on page 196. The details
have been cited in Part (I), Section - I (D).














IR SPECTRAL STUDY OF 2-THIO-4-p-ANISYL-6-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-
1,2,3,4-TETRAHYDROPYRIMIDINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2939 2975-2950 549
-CH3 C-H str. (sym.) 2893 2880-2860 "
C-H def. (asym.) 1425 1470-1435 "
C-H def. (sym.) 1369 1390-1370 "
Aromatic C-H str. 3053 3080-3030 550
C=C str. 1479 1520-1480 "
C-H i.p. def. 1055 1070-1000 "
C-H o.o.p. def. 810 835-810 "
Furyl C=O str. 1687 1720-1655 549
moiety C-O-C str. (sym.) 1272 1275-1200 "
C-O-C str. (asym.) 1055 1075-1020 "
(overlapped)
Thio- N-H str. 3350 3400-3250 551
pyrimidine C=S str. 1172 1200-1050 549

































PMR SPECTRAL STUDY OF 2-THIO-4-p-ANISYL-6-(p-2'-CARBOXYFURAN-5'-YL
PHENYL)-1,2,3,4-TETRAHYDROPYRIMIDINE
Internal Standard : TMS
Solvent : CDCl3+DMSOd6
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.78 - 3H singlet Ar-OCH3
2 6.82 - 1H singlet Ar-Hg
3 6.87 Jfe=6 1H doublet Ar-Hf
4 6.90 Jab=9 2H doublet Ar-Ha,a'
5 7.23 Jef=6 1H doublet Ar-He
6 7.30 Jcd=9 2H doublet Ar-H c,c'
7 7.58 Jdc=9 2H doublet Ar-Hd,d'
8 7.75 Jba=9 2H doublet Ar-H b,b'
9 7.80 - 1H singlet Ar-Hh
10 8.72 - 1H singlet -NH
11 9.22 - 1H singlet -NH











































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-THIO-4-ARYL-
6-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-1,2,3,4-TETRAHYDRO
PYRIMIDINES
[A] Synthesis of 5-p-Acetophenylfuran-2-carboxylic acid
See part (I), Section - I (A).
[B] Synthesis of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-p-anisyl-2-
propene-1-one
See part (I), Section - I (B).
[C] Synthesis of 2-Thio-4-p-anisyl-6-(p-2'-carboxyfuran-5'-yl phenyl)-
1,2,3,4-tetrahydropyrimidine
Mixture of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-p-anisyl-2-propen-1-one
(3.48 g, 0.01 M), thiourea (0.76 g, 0.01 M) in alc. KOH was added and refluxed
for 6 hrs. The contents were then poured onto crushed ice and neutralised with
dil. HCl solution. The product obtained was isolated, filtered and crystallised
from ethanol. Yield 68%(2.7g), m.p. 261oC, (C22H18O4N2S ; Required:
C, 65.02; H, 4.43; N, 6.90 ; Found: C, 64.83; H, 4.58; N, 6.84%). TLC solvent
system: Acetone : Benzene (3 : 7).
Similarly other thiopyrimidines were prepared. The physical data are
recorded in Table No. 12.
[D] Antimicrobial activity of 2-Thio-4-aryl-6-(p-2'-carboxyfuran-5' yl
phenyl)-1,2,3,4-tetrahydropyrimidines
Antimicrobial testing was carried out as described in Part-I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 12.
193
TABLE NO. 12 : PHYSICAL CONSTANTS OF 2-THIO-4-ARYL-6-(p-2'-CARBOXYFURAN-5' YL PHENYL)-1,2,3,4-
TETRAHYDROPYRIMIDINES
12a C6H5- C21H16O3N2S 376 191 0.63 75 7.44 7.38
12b 4-OCH3-C6H4- C22H18O4N2S 406 221 0.55 68 6.90 6.84
12c 2-Cl-C6H4- C21H15O3N2SCl 410 177 0.83 73 6.82 6.76
12d 4-Cl-C6H4- C21H15O3N2SCl 410 218 0.71 71 6.82 6.75
12e 3,4-(OCH3)2-C6H3- C23H20O5N2S 436 181 0.81 76 6.42 6.37
12f 2-OH-C6H4- C21H16O4N2S 392 107 0.78 81 7.14 7.09
12g 4-OH-C6H4- C21H16O4N2S 392 211 0.72 70 7.14 7.07
12h 3-OCH3-4-OH-C6H3- C22H18O5N2S 422 197 0.58 76 6.63 6.57
12i -CH=CH-C6H5 C23H18O3N2S 402 278 0.68 72 6.96 6.91
12j 2-NO2-C6H4- C21H15O5N3S 421 206 0.55 78 9.97 9.92
12k 3-NO2-C6H4- C21H15O5N3S 421 >270 0.38 75 9.97 9.91
12l α-C4H3O- C19H14O4N2S 366 >270 0.56 82 7.65 7.58
12m 3-OC6H5-C6H4- C27H20O4N2S 468 186 0.67 79 5.98 5.91



















































B. mega 13 17 19 15 18 16 17 11 22 15 19 17 16 23 22 2
S.aureus 16 14 13 15 15 14 12 16 17 14 15 11 13 22 23 1
P.vulgaris 14 12 12 14 15 11 13 14 13 11 14 12 14 15 18 1
E.coli 17 14 12 18 16 15 16 16 17 15 18 21 19 21 21 2
A.niger 20 19 21 23 19 18 17 16 19 21 22 19 16 0 0 0







GRAPHICAL CHART NO. 12 : ANTIMICROBIAL ACTIVITY OF 2-THIO-4-ARYL-6-( P-2’-CARBOXYFURAN-5’-YL PHENYL)-
1,2,3,4-TETRAHYDROPYRIMIDINES
COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-III
Section -  I  :  Antimicrobial  activity of  2-Thio-4-aryl-6-(p-2 ' -carboxyfuran-5 ' -yl  phenyl) -1,2,3,4-
tetrahydropyrimidines
12i (22) 12i (17) 12d (18) 12e (15) 12d (23)
12k (18) 12k (22)
12l (21)
12m (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






The emerging role of barbitones in pharmaceutical chemistry as well as in
biochemistry stimulated termendous interest in the synthesis of barbitones with
therapeutic potential most important is the effect of barbiturates on the central
nervous system. Barbituric acid derivatives constitute an important class of
compounds possessing diverse type of biological properties including hypnotic,
sedative, anticonvulsant, cardiovascular etc. The first member of hypnotic drugs
series was barbital (I).
Barbituric acid ring system has been found in many natural products like
alkaloids, which includes Xanthine (II) and Theophyline (III) are constituents of
tea leaves. Theobromine is found in coca beans.
SYNTHETIC ASPECT
Dif ferent  methods are used for  the preparat ion of  barbi tones in
literature524,525.


























2. Cao-Yun Weu et al.527 have prepared barbituric acid derivatives by the
reaction of different aldehydes with barbituric acid in basic media.
3. Ogus Funda et al528 have synthesised barbiturates by the reaction between
acetone and barbituric acid.
THERAPEUTIC IMPORTANCE
At present great interest is being taken in barbituric acid derivatives because
of its biological activity and their relation with nucleic acids, viz uracil, thymine
and cytosine.
Derivatives of barbituric acid are perhaps the most widely used pyrimidines
in medicine. Veronal (IV) and Luminol (V) possess hypnotics activities. While



















































Some barbituric acid derivatives used as sedative and hypnotic is
carbubarb529, which is used as veternary anaesthetics. Some isoxazolo
pyrimidine derivatives have been studied because of their potential as
pesticidal530,531 activity. Some barbiturates showing cardiovascular532-534 and
analgesic and antiinflammatory activities535 have been reported.
Raymond et al.536 synthesised some barbiturates (VII) which showed
anticancer activity.
Mahmoud et al.537 have synthesised barbituric acid derivatives and reported
their antimicrobial activity. Ulf Wellmar et al.538 have prepared some uracil
derivatives and screened for antiviral activity539,540. Some isoxazolo pyrimidine
derivatives have been extensively studied and reported as antagonist541 and
antitumor542 activity. Wolf-Gang et al.543 have reported 5-(3-benzylthiazolidin-
2-ylidene)-1,3-dimethyl hexahydro pyrimidine-2,4,6-trion having agricultural
activity. Andre Roland et al.544 demonstrated some barbituric acid derivatives
used as herbicidal and insecticides. Omar M. T.545 have synthesised barbitones,
showing antimicrobial activity. Sakai et al.546 have synthesised some new
barbitone derivatives which were assessed for bone and cartilage disease.
R. T. Pardasani547 have prepared barbitone derivatives useful as antibacterial


























Keeping in view the important biological activities possessed by barbituric
acid derivatives, we have tried to synthesised some new barbitones having better
therapeutic activities.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
5-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-5-(1-ARYL
VINYL) METHINO BARBITURIC ACIDS
Barbitones... 200
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5- (p-2 ' -
CARBOXYFURAN-5'-YL PHENYL)-5-(1-ARYL VINYL) METHINO
BARBITURIC ACIDS
During the past years, considerable evidence has been accumulated to
demonstrate the efficiency of barbituric acid derivatives. Considering this
background, some new barbituric acid derivatives of type (XIII) were prepared
by the condensation of compounds of type (X) with barbituric acid in glacial
aceticacid, as shown in Reaction Scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R = p-Anisyl = 458, m/z = 460 (m + 2).
The products have been screened for their in vitro biological activity like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37 Rv
at a concentration of 6.25 µg using Rifampin as a standard drug, antibacterial
activities towards Gram positive and Gram negative bacterial strains and antifungal
activity towards Aspergillus niger at  a  concentration of 40 µg. The biological
activities of the synthesised compounds were compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known antibiotics recorded on page 210. The details have been cited in
















IR SPECTRAL STUDY OF 5- (p-2'-CARBOXYFURAN-5'-YLPHENYL)-5-[1-(m,p-
DIMETHOXYPHENYL VINYL)] METHINO BARBITURIC ACID
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2964 2975-2950 549
-CH3 C-H str. (sym.) 2866 2880-2860 "
C-H def. (asym.) 1456 1470-1435 "
C-H def. (sym.) 1367 1390-1370 "
Aromatic C-H str. 3058 3080-3030 550
C=C str. 1481 1520-1480 "
C-H i.p. def. 1020 1070-1000 "
C-H o.o.p. def. 829 835-810 "
Furyl C=O str. 1685 1720-1655 549
moiety C-O-C str. (sym.) 1228 1275-1200 "
C-O-C str. (asym.) 1020 1075-1020 "
(overlapped)
Barbitone N-H str. 3215 3450-3250 "
C=O str. 1699 1750-1700 "









































PMR SPECTRAL STUDY OF 5-(p-2'-CARBOXYFURAN-5'-YL PHENYL)-5-[1-(m,p-
DIMETHOXYPHENYL VINYL)] METHINO BARBITURIC ACID
0Internal Standard : TMS
Solvent : CDCl3+DMSOd6
Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.93 - 3H singlet Ar-OCH3
2 3.96 - 3H singlet Ar-OCH3
3 6.92 Jab=3 1H doublet Ar-Ha
4 6.94 Jfe=3 1H doublet Ar-Hf
5 7.22 - 1H singlet Ar-Hb
6 7.25 - 1H singlet Ar-He'
7 7.27 Jef=3 1H doublet Ar-He
8 7.45 Jgh=15 1H doublet Ar-Hg
9 7.77 Jhg=15 1H doublet Ar-Hh
10 7.91 Jdc=9 2H doublet Ar-Hd,d'
11 8.07 Jcd=9 2H doublet Ar-H c,c']













































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 5- (p-2 ' -
CARBOXYFURAN-5'-YL PHENYL)-5-(1-ARYL VINYL) METHINO
BARBITURIC ACIDS
[A] Synthesis of 5-p-Acetophenylfuran-2-carboxylic acid
See part (I), Section - I (A).
[B] Synthesis of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-aryl-2-propene-1-
ones
See part (I), Section - I (B).
[C] Synthesis of  5-(p-2 ' -Carboxyfuran-5 '  yl  phenyl) -5-[1-(m,p-
dimethoxyphenyl)vinyl] methino barbituric acid
Mixture of 1-(p-2'-Carboxyfuran-5'-yl phenyl)-3-(m,p-dimethoxyphenyl)-2-
propene-1-one (3.78 g, 0.01 M) in ethanol & barbituric acid (1.28 g, 0.01 M) in
glacial aceticacid was refluxed for 8 hrs. on oil bath. The contents were poured
into ice and product was isolated, crystallised from ethanol. Yield 66%(3.2g),
m. p. 217oC, (C26H20O8N2 ; Required : C, 63.93; H, 4.10; N, 5.74 ; Found :
C, 64.07; H, 4.21; N, 5.69%). TLC solvent system : Acetone : Benzene (5 : 5).
Similarly other barbitones were prepared. The physical data are recorded
in Table No. 13.
[D] Antimicrobial activity of 5-(p-2'-Carboxyfuran-5' yl phenyl)-5-(1-
aryl vinyl) methino barbituric acids
Antimicrobial testing was carried out as described in Part - I, Section - I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 13.
The antitubercular activity of the compounds of type (XIII) was carried out
by TAACF, the Southern Research Institute, U.S.A. as described in Part - I,
Section - I (D), and the percentage of inhibition data of the compounds are recorded
in Table No. 13a.
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TABLE NO. 13 : PHYSICAL CONSTANTS OF 5-(p-2'-CARBOXYFURAN-5' YL PHENYL)-5-(1-ARYL VINYL)
METHINO BARBITURIC ACIDS
13a C6H5- C24H16O6N2 428 218 0.52 65 6.54 6.47
13b 4-OCH3-C6H4- C25H18O7N2 458 210 0.81 69 6.11 6.03
13c 2-Cl-C6H4- C24H15O6N2Cl 462.5 232 0.65 71 6.05 5.96
13d 4-Cl-C6H4- C24H15O6N2Cl 462.5 218 0.32 80 6.05 5.98
13e 3,4-(OCH3)2-C6H3- C26H20O8N2 488 217 0.82 66 5.74 5.69
13f 2-OH-C6H4- C24H16O7N2 444 >270 0.71 73 6.30 6.23
13g 4-OH-C6H4- C24H16O7N2 444 229 0.50 65 6.30 6.25
13h 3-OCH3-4-OH-C6H3- C25H18O8N2 474 243 0.78 61 5.90 5.84
13i -CH=CH-C6H5 C26H18O6N2 454 203 0.79 74 6.16 6.09
13j 2-NO2-C6H4- C24H15O8N3 473 244 0.68 66 8.88 8.81
13k 3-NO2-C6H4- C24H15O8N3 473 >270 0.65 68 8.88 8.79
13l α-C4H3O- C22H14O7N2 418 >270 0.55 68 6.70 6.63
13m 3-OC6H5-C6H4- C30H20O7N2 520 174 0.69 63 5.38 5.31
13n 2,7-(Cl)2-C9H4N- C27H15O6N3Cl2 536 186 0.62 68 7.84 7.77



























COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-IV
Section - I : Antimicrobial activity of 5-(p-2'-Carboxyfuran-5'-yl phenyl)-5-(1-aryl vinyl)methinobarbituric
acids
13a (21) 13g (23) 13a (18) 13j (17) 13f (21)
13l (17) 13h (18) 13h (22)
13i (21)
13j (23)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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TABLE NO. 13a : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
171618 AB-124 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 15
171624 AB-130 3-OCH3-4-OH-C6H3- Sau.uni Alamar H37Rv >6.25 14  ''
171619 AB-125 2-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 5  ''
171621 AB-127 α-C4H3O- Sau.uni Alamar H37Rv >6.25 3  ''
171623 AB-129 3-OC6H5-C6H4- Sau.uni Alamar H37Rv >6.25 1  ''
171620 AB-126 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
171622 AB-128 -CH=CH-C6H5 Sau.uni Alamar H37Rv >6.25 0  ''
171625 AB-131 2,7-(Cl)2-C9H4N- Sau.uni Alamar H37Rv >6.25 0  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.025mg/ml































B. mega 21 14 15 18 17 19 12 15 16 17 13 18 20 23 22 24
S.aureus 16 12 15 14 16 16 23 14 11 15 15 17 14 22 23 17
P.vulgaris 11 11 14 12 13 14 14 13 12 17 11 14 13 15 18 17
E.coli 18 15 11 14 16 17 15 18 16 16 17 14 15 21 21 23
A.niger 20 19 20 18 16 21 19 22 21 23 19 20 18 0 0 0
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